Identification
NameGemcitabine
Accession NumberDB00441  (APRD00201)
TypeSmall Molecule
GroupsApproved
Description

Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as new nucleosides cannot be attached to the "faulty" nucleoside, resulting in apoptosis (cellular "suicide"). Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It is being investigated for use in oesophageal cancer, and is used experimentally in lymphomas and various other tumor types.

Structure
Thumb
Synonyms
2'-Deoxy-2',2'-difluorocytidine
2',2'-Difluorodeoxycytidine
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Gemcitabin
Gemcitabina
Gemcitabine
Gemcitabinum
External IDs LY-188011 / LY188011
Product Ingredients
IngredientUNIICASInChI KeyDetails
Gemcitabine HydrochlorideU347PV74IL 122111-03-9OKKDEIYWILRZIA-OSZBKLCCSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act GemcitabineSolution38 mgIntravenousActavis Pharma Company2016-05-02Not applicableCanada
Act GemcitabinePowder, for solution1 gIntravenousActavis Pharma CompanyNot applicableNot applicableCanada
Act GemcitabinePowder, for solution200 mgIntravenousActavis Pharma CompanyNot applicableNot applicableCanada
Aj-gemcitabinePowder, for solution2 gIntravenousAgila Jamp Canada IncNot applicableNot applicableCanada
Aj-gemcitabinePowder, for solution200 mgIntravenousAgila Jamp Canada IncNot applicableNot applicableCanada
Aj-gemcitabinePowder, for solution1 gIntravenousAgila Jamp Canada IncNot applicableNot applicableCanada
GemcitabineInjection, solution38 mg/mLIntravenousHospira, Inc.2011-08-04Not applicableUs
GemcitabineInjection, solution38 mg/mLIntravenousHospira, Inc.2011-08-04Not applicableUs
GemcitabineInjection, solution38 mg/mLIntravenousHospira, Inc.2011-08-04Not applicableUs
Gemcitabine for InjectionPowder, for solution2 gIntravenousAccord Healthcare Limited2011-08-31Not applicableCanada
Gemcitabine for InjectionPowder, for solution200 mgIntravenousTeva2008-09-10Not applicableCanada
Gemcitabine for InjectionPowder, for solution1 gIntravenousTeligent OuNot applicableNot applicableCanada
Gemcitabine for InjectionPowder, for solution200 mgIntravenousAccord Healthcare Limited2011-08-31Not applicableCanada
Gemcitabine for InjectionPowder, for solution2 gIntravenousFresenius KabiNot applicableNot applicableCanada
Gemcitabine for InjectionPowder, for solution1 gIntravenousTeva2008-06-27Not applicableCanada
Gemcitabine for InjectionPowder, for solution200 mgIntravenousFresenius KabiNot applicableNot applicableCanada
Gemcitabine for InjectionPowder, for solution1 gIntravenousAccord Healthcare Limited2009-07-16Not applicableCanada
Gemcitabine for InjectionPowder, for solution200 mgIntravenousTeligent OuNot applicableNot applicableCanada
Gemcitabine for InjectionPowder, for solution1 gIntravenousFresenius KabiNot applicableNot applicableCanada
Gemcitabine for Injection ConcentrateSolution100 mgIntravenousAccord Healthcare Limited2014-04-17Not applicableCanada
Gemcitabine for Injection USPPowder, for solution1 gIntravenousGeneric Medical Partners IncNot applicableNot applicableCanada
Gemcitabine for Injection USPPowder, for solution200 mgIntravenousGeneric Medical Partners IncNot applicableNot applicableCanada
Gemcitabine for Injection, USPPowder, for solution200 mgIntravenousHospira, Inc.2008-01-25Not applicableCanada
Gemcitabine for Injection, USPPowder2 gIntravenousDr Reddy's LaboratoriesNot applicableNot applicableCanada
Gemcitabine for Injection, USPPowder, for solution200 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Gemcitabine for Injection, USPPowder200 mgIntravenousDr Reddy's LaboratoriesNot applicableNot applicableCanada
Gemcitabine for Injection, USPPowder, for solution1 gIntravenousHospira, Inc.2007-12-272014-08-01Canada
Gemcitabine for Injection, USPPowder, for solution1 gIntravenousMylan Pharmaceuticals2014-06-262017-05-08Canada
Gemcitabine for Injection, USPPowder1 gIntravenousDr Reddy's LaboratoriesNot applicableNot applicableCanada
Gemcitabine for Injection, USPPowder, for solution2 gIntravenousHospira, Inc.2009-10-01Not applicableCanada
Gemcitabine for Injection, USPPowder, for solution2 gIntravenousMylan Pharmaceuticals2014-06-262017-05-08Canada
Gemcitabine Hydrochloride for InjectionPowder, for solution200 mgIntravenousSandoz Canada Incorporated2007-11-20Not applicableCanada
Gemcitabine Hydrochloride for InjectionPowder, for solution1 gIntravenousSandoz Canada Incorporated2007-11-20Not applicableCanada
Gemcitabine InjectionSolution40 mgIntravenousSandoz Canada Incorporated2013-09-24Not applicableCanada
Gemcitabine InjectionSolution38 mgIntravenousHospira, Inc.2013-03-20Not applicableCanada
Gemcitabine InjectionSolution38 mgIntravenousApotex CorporationNot applicableNot applicableCanada
Gemcitabine Sun for InjectionPowder, for solution200 mgIntravenousTaro Pharmaceuticals, Inc.2013-03-21Not applicableCanada
Gemcitabine Sun for InjectionPowder, for solution1 gIntravenousTaro Pharmaceuticals, Inc.2013-03-21Not applicableCanada
GemzarInjection, powder, lyophilized, for solution200 mg/5mLIntravenousEli Lilly & Co. Ltd.1996-05-15Not applicableUs
GemzarInjection, powder, lyophilized, for solution1 g/25mLIntravenousEli Lilly & Co. Ltd.1996-05-15Not applicableUs
Gemzar (1gm/vial)Powder, for solution1 gIntravenousEli Lilly & Co. Ltd.1997-04-172015-11-01Canada
Gemzar (200mg/vial)Powder, for solution200 mgIntravenousEli Lilly & Co. Ltd.1997-04-172015-03-11Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GemcitabineInjection, powder, lyophilized, for solution38 mg/mLIntravenousHospira, Inc.2011-07-25Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution200 mg/5.26mLIntravenousFresenius Kabi2011-07-26Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution38 mg/mLIntravenousHospira, Inc.2010-11-15Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution1 g/25mLIntravenousSagent Pharmaceuticals2014-12-29Not applicableUs
GemcitabineInjection38 mg/mLIntravenousActavis Pharma Company2016-04-12Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution200 mg/5mLIntravenousDr Reddy's Laboratories2011-07-25Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution200 mg/5mLIntravenousSagent Pharmaceuticals2014-12-29Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution38 mg/mLIntravenousHospira, Inc.2011-07-25Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution1 g/25mLIntravenousSun Pharma Global FZE2011-07-252018-11-30Us
GemcitabineInjection, powder, lyophilized, for solution200 mg/5mLIntravenousSagent Pharmaceuticals2011-07-25Not applicableUs
GemcitabineInjection38 mg/mLIntravenousActavis Pharma Company2016-04-12Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution1 g/26.3mLIntravenousFresenius Kabi2011-07-26Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution200 mg/5mLIntravenousAthenex Pharmaceutical Division, Llc.2017-07-31Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution1 g/25mLIntravenousDr Reddy's Laboratories2011-07-25Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution2 g/50mLIntravenousFresenius Kabi2011-05-16Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution1 g/25mLIntravenousSagent Pharmaceuticals2011-07-25Not applicableUs
GemcitabineInjection38 mg/mLIntravenousActavis Pharma Company2016-04-12Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution1 g/25mLIntravenousAthenex Pharmaceutical Division, Llc.2017-07-31Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution40 mg/mLIntravenousBedford Pharmaceuticals2012-03-19Not applicableUs
GemcitabineInjection, powder, lyophilized, for solution200 mg/5mLIntravenousSun Pharma Global FZE2011-07-252018-09-30Us
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution2 g/50mLIntravenousActavis Pharma Company2016-10-03Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution200 mg/5mLIntravenousPfizer Laboratories Div Pfizer Inc.2011-07-25Not applicableUs
Gemcitabine hydrochlorideInjection, powder, lyophilized, for solution1 g/25mLIntravenousHeritage2012-10-22Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution200 mg/5mLIntravenousWatson Pharmaceuticals2011-07-25Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution2 g/50mLIntravenousAccord Healthcare Limited2011-07-25Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution2 g/50mLIntravenousMylan Institutional2011-07-25Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution1 g/25mLIntravenousCipla Limited2011-07-25Not applicableUs
GEMCITABINE HydrochlorideInjection, powder, lyophilized, for solution200 mg/5mLIntravenousActavis Pharma Company2015-01-05Not applicableUs
Gemcitabine hydrochlorideInjection, powder, lyophilized, for solution1 g/25mLIntravenousHeritage2012-10-22Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution200 mg/5mLIntravenousGland Pharma Limited2016-02-01Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution200 mg/5mLIntravenousAccord Healthcare Limited2011-07-25Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution38 mg/mLIntravenousBlue Point Laboratories2011-07-25Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution1 g/25mLIntravenousPfizer Laboratories Div Pfizer Inc.2011-07-25Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution200 mg/5mLIntravenoushameln rds gmbh2012-09-20Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution1 g/25mLIntravenousWatson Pharmaceuticals2011-07-25Not applicableUs
Gemcitabine hydrochlorideInjection, powder, lyophilized, for solution200 mg/5mLIntravenousHeritage2012-10-22Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution200 mg/5mLIntravenousMylan Institutional2011-07-25Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution1 g/25mLIntravenousActavis Pharma Company2015-01-05Not applicableUs
Gemcitabine hydrochlorideInjection, powder, lyophilized, for solution200 mg/5mLIntravenousHeritage2012-10-22Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution1 g/25mLIntravenousGland Pharma Limited2016-02-01Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution1 g/25mLIntravenousAccord Healthcare Limited2011-07-25Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution1 g/25mLIntravenousMylan Institutional2011-07-25Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution200 mg/5mLIntravenousCipla Limited2011-07-25Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution2 g/50mLIntravenousPfizer Laboratories Div Pfizer Inc.2011-07-25Not applicableUs
Gemcitabine HydrochlorideInjection, powder, lyophilized, for solution1 g/25mLIntravenoushameln rds gmbh2012-09-20Not applicableUs
Gemcitabine hydrochlorideInjection, powder, lyophilized, for solution200 mg/5mLIntravenousHeritage2012-10-22Not applicableUs
Gemcitabine hydrochlorideInjection, powder, lyophilized, for solution1 g/25mLIntravenousHeritage2012-10-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbineDosa
AbingemMiracalus
AcytabinIntas
CelgemAlkem
CelzarCelon
CytogemDr Reddys
DaplaxDr Reddys
DercinEgis
EriogemEriochem
FotinexFada
GebinaAspen
GembioBioprofarma
GemciredDr Reddys
GemitaFresenius
GeztRichmond
GitrabinActavis
GramagenLilly
JemtaSandoz
NallianGedeon Richter
OncogemGrey Inversiones
RibozarRibosepharm
TabinCrinos
XtrozRanbaxy
Brand mixturesNot Available
Categories
UNIIB76N6SBZ8R
CAS number95058-81-4
WeightAverage: 263.1981
Monoisotopic: 263.071762265
Chemical FormulaC9H11F2N3O4
InChI KeySDUQYLNIPVEERB-QPPQHZFASA-N
InChI
InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
IUPAC Name
4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one
SMILES
NC1=NC(=O)N(C=C1)[[email protected]@H]1O[[email protected]](CO)[[email protected]@H](O)C1(F)F
Pharmacology
Indication

Gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; metastatic ovarian cancer; inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer; and locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.

Structured Indications
Pharmacodynamics

Gemcitabine is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (or DNA synthesis phase of the cell cycle), stopping normal development and division. Gemcitabine blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Gemcitabine blocks the incorporation of the thymidine nucleotide into the DNA strand. It demonstrates dose-dependent synergistic activity with cisplatin in vitro. In vivo, gemcitabine showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Gemcitabine was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to gemcitabine 4 hours before cisplatin produced the greatest interaction.

Mechanism of action

Gemcitabine inhibits thymidylate synthetase, leading to inhibition of DNA synthesis and cell death. Gemcitabine is a prodrug so activity occurs as a result of intracellular conversion to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate by deoxycitidine kinase. Gemcitabine diphosphate also inhibits ribonucleotide reductase, the enzyme responsible for catalyzing synthesis of deoxynucleoside triphosphates required for DNA synthesis. Finally, Gemcitabine triphosphate (diflurorodeoxycytidine triphosphate) competes with endogenous deoxynucleoside triphosphates for incorporation into DNA.

TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideyes
cross-linking/alkylation
Humannot applicabledetails
Ribonucleoside-diphosphate reductase large subunitProteinyes
inhibitor
HumanP23921 details
Thymidylate synthaseProteinunknown
inhibitor
HumanP04818 details
UMP-CMP kinaseProteinunknown
inhibitor
HumanP30085 details
Related Articles
Absorption

The pharmacokinetics of gemcitabine are described by a 2-compartment model.

Volume of distribution
  • 50 L/m^2 [infusions lasting <70 minutes]
  • 370 L/m^2 [long infusions]
Protein binding

Plasma protein binding is negligible (<10%)

Metabolism

Transformed via nucleoside kinases to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate. Can also undergo deamination via cytidine deaminase to an inactive uracil metabolite (dFdU).

SubstrateEnzymesProduct
Gemcitabine
Gemcitabine MonophosphateDetails
Gemcitabine Monophosphate
Difluorodeoxyuridine monophosphateDetails
Gemcitabine Monophosphate
Gemcitabine diphosphateDetails
Gemcitabine diphosphate
Gemcitabine triphosphateDetails
Route of elimination

Within one (1) week, 92% to 98% of the dose was recovered, almost entirely in the urine. Gemcitabine (<10%) and the inactive uracil metabolite, 2´-deoxy-2´,2´-difluorouridine (dFdU), accounted for 99% of the excreted dose.

Half life

Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.

Clearance
  • 92.2 L/hr/m2 [Men 29 yrs]
  • 75.7 L/hr/m2 [Men 45 yrs]
  • 55.1 L/hr/m2 [Men 65 yrs]
  • 40.7 L/hr/m2 [Men 79 yrs]
  • 69.4 L/hr/m2 [Women 29 yrs]
  • 57 L/hr/m2 [Women 45 yrs]
  • 41.5 L/hr/m2 [Women 65 yrs]
  • 30.7 L/hr/m2 [Women 79 yrs]
Toxicity

Myelosuppression, paresthesias, and severe rash were the principal toxicities, LD50=500 mg/kg (orally in mice and rats)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Gemcitabine Action PathwayDrug actionSMP00446
Gemcitabine Metabolism PathwayDrug metabolismSMP00603
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Ribonucleoside-diphosphate reductase large subunit---(A;A)---ADR Directly StudiedPatients with this genotype have increased risk of neutropenia and neurotoxicity with gemcitabine. Details
Interactions
Drug Interactions
DrugInteractionDrug group
AcetaminophenThe serum concentration of Gemcitabine can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Gemcitabine.Approved
AfatinibThe serum concentration of Gemcitabine can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Gemcitabine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Gemcitabine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Gemcitabine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Gemcitabine can be increased when it is combined with Alfentanil.Approved, Illicit
AmantadineThe serum concentration of Gemcitabine can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Gemcitabine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Gemcitabine can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Gemcitabine can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Gemcitabine can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Gemcitabine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Gemcitabine can be increased when it is combined with Amsacrine.Approved
AstemizoleThe serum concentration of Gemcitabine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Gemcitabine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Gemcitabine can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Gemcitabine can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Gemcitabine can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Gemcitabine can be increased when it is combined with Azithromycin.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Gemcitabine.Investigational
BenzocaineThe serum concentration of Gemcitabine can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Gemcitabine can be increased when it is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Gemcitabine.Approved, Investigational
BiperidenThe serum concentration of Gemcitabine can be increased when it is combined with Biperiden.Approved
BleomycinThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Bleomycin.Approved
BosutinibThe serum concentration of Gemcitabine can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Gemcitabine can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Gemcitabine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Gemcitabine can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemcitabine.Approved
CaffeineThe serum concentration of Gemcitabine can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Gemcitabine can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Gemcitabine can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Gemcitabine can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Gemcitabine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Gemcitabine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Gemcitabine can be increased when it is combined with Caspofungin.Approved
ChloroquineThe serum concentration of Gemcitabine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Gemcitabine can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Gemcitabine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Gemcitabine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Gemcitabine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Gemcitabine can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Gemcitabine can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Gemcitabine can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Gemcitabine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Gemcitabine can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Gemcitabine can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of Gemcitabine can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Gemcitabine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe serum concentration of Gemcitabine can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Clozapine.Approved
CobicistatThe serum concentration of Gemcitabine can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Gemcitabine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Gemcitabine can be increased when it is combined with Colforsin.Experimental
CrizotinibThe serum concentration of Gemcitabine can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Gemcitabine.Approved, Investigational
CyclosporineThe serum concentration of Gemcitabine can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DaclatasvirThe serum concentration of Gemcitabine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Gemcitabine can be increased when it is combined with Dactinomycin.Approved
DasatinibThe serum concentration of Gemcitabine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Gemcitabine can be decreased when it is combined with Daunorubicin.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Gemcitabine.Approved
DesipramineThe serum concentration of Gemcitabine can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Gemcitabine.Approved
DesloratadineThe serum concentration of Gemcitabine can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Gemcitabine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Gemcitabine can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Gemcitabine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Gemcitabine.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Gemcitabine.Approved
DihydroergotamineThe serum concentration of Gemcitabine can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Gemcitabine can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Gemcitabine can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemcitabine.Approved, Investigational
DoxazosinThe serum concentration of Gemcitabine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Gemcitabine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Gemcitabine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Gemcitabine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Gemcitabine can be increased when it is combined with Dronedarone.Approved
ElbasvirThe serum concentration of Gemcitabine can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Gemcitabine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Gemcitabine can be increased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Gemcitabine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Gemcitabine can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Gemcitabine can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EstramustineThe serum concentration of Gemcitabine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Gemcitabine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Gemcitabine can be decreased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Gemcitabine can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Gemcitabine can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Gemcitabine can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Gemcitabine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Gemcitabine can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Gemcitabine can be increased when it is combined with Fidaxomicin.Approved
FingolimodGemcitabine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Gemcitabine can be increased when it is combined with Fluconazole.Approved
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Gemcitabine.Approved
FluoxetineThe serum concentration of Gemcitabine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Gemcitabine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Gemcitabine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Gemcitabine can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Gemcitabine can be increased when it is combined with Fluvoxamine.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Gemcitabine is combined with G17DT.Investigational
GefitinibThe serum concentration of Gemcitabine can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Gemcitabine can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Gemcitabine is combined with GI-5005.Investigational
GlyburideThe serum concentration of Gemcitabine can be increased when it is combined with Glyburide.Approved
Gramicidin DThe serum concentration of Gemcitabine can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Gemcitabine can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Gemcitabine can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Gemcitabine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Gemcitabine can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Gemcitabine can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Gemcitabine can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Gemcitabine can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Gemcitabine can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Gemcitabine is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Gemcitabine is combined with INGN 225.Investigational
IsavuconazoniumThe serum concentration of Gemcitabine can be increased when it is combined with Isavuconazonium.Approved, Investigational
ItraconazoleThe serum concentration of Gemcitabine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Gemcitabine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Gemcitabine can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Gemcitabine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Gemcitabine can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Gemcitabine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Gemcitabine can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Leflunomide.Approved, Investigational
LevofloxacinThe serum concentration of Gemcitabine can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Gemcitabine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Gemcitabine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Gemcitabine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Gemcitabine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Gemcitabine can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Gemcitabine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Gemcitabine can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Gemcitabine can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Gemcitabine can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Gemcitabine can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Gemcitabine can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Gemcitabine can be decreased when it is combined with Lumacaftor.Approved
MaprotilineThe serum concentration of Gemcitabine can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Gemcitabine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Gemcitabine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Gemcitabine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Gemcitabine can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Gemcitabine.Withdrawn
MethadoneThe serum concentration of Gemcitabine can be increased when it is combined with Methadone.Approved
MetoprololThe serum concentration of Gemcitabine can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Gemcitabine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Gemcitabine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Gemcitabine can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Gemcitabine can be decreased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe serum concentration of Gemcitabine can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Gemcitabine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Gemcitabine can be increased when it is combined with Morphine.Approved, Investigational
NaltrexoneThe serum concentration of Gemcitabine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Gemcitabine can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Gemcitabine can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Gemcitabine can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Gemcitabine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Gemcitabine can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Gemcitabine can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Gemcitabine can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Gemcitabine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Gemcitabine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Gemcitabine can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Gemcitabine can be decreased when it is combined with Norethisterone.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Gemcitabine.Experimental
OmeprazoleThe serum concentration of Gemcitabine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Gemcitabine.Approved
P-NitrophenolThe serum concentration of Gemcitabine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemcitabine.Approved, Vet Approved
Palmitic AcidThe serum concentration of Gemcitabine can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Gemcitabine can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Gemcitabine can be increased when it is combined with Paroxetine.Approved, Investigational
PerindoprilThe serum concentration of Gemcitabine can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Gemcitabine can be decreased when it is combined with Phenobarbital.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemcitabine.Approved, Investigational
PimozideThe serum concentration of Gemcitabine can be increased when it is combined with Pimozide.Approved
Platelet Activating FactorThe serum concentration of Gemcitabine can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Gemcitabine can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Gemcitabine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Gemcitabine can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Gemcitabine can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Gemcitabine can be increased when it is combined with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of Gemcitabine can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Gemcitabine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Gemcitabine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Gemcitabine can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Gemcitabine can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Gemcitabine can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Gemcitabine can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Gemcitabine can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Gemcitabine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Gemcitabine can be increased when it is combined with Quinine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Rabies vaccine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Gemcitabine.Approved
RanitidineThe serum concentration of Gemcitabine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Gemcitabine can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Gemcitabine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Gemcitabine can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Gemcitabine can be decreased when it is combined with Reserpine.Approved
RifampicinThe serum concentration of Gemcitabine can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Gemcitabine can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Gemcitabine is combined with CDX-110.Investigational
RitonavirThe serum concentration of Gemcitabine can be decreased when it is combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Gemcitabine.Approved
RolapitantThe serum concentration of Gemcitabine can be increased when it is combined with Rolapitant.Approved
SaquinavirThe serum concentration of Gemcitabine can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Gemcitabine can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Gemcitabine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Gemcitabine can be increased when it is combined with Sertraline.Approved
SimeprevirThe serum concentration of Gemcitabine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Gemcitabine can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemcitabine.Approved
SirolimusThe serum concentration of Gemcitabine can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Gemcitabine can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Gemcitabine can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Gemcitabine is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Gemcitabine can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of Gemcitabine can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Gemcitabine can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Gemcitabine can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Gemcitabine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Gemcitabine can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Gemcitabine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Gemcitabine.Approved, Investigational
TacrolimusThe serum concentration of Gemcitabine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Gemcitabine can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Gemcitabine can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe serum concentration of Gemcitabine can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Gemcitabine can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Gemcitabine can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Gemcitabine can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Gemcitabine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Gemcitabine can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Gemcitabine is combined with TG4010.Investigational
TicagrelorThe serum concentration of Gemcitabine can be increased when it is combined with Ticagrelor.Approved
TofacitinibGemcitabine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Gemcitabine can be increased when it is combined with Tolvaptan.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Gemcitabine.Approved, Investigational
TrazodoneThe serum concentration of Gemcitabine can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Gemcitabine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Gemcitabine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Gemcitabine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Gemcitabine can be increased when it is combined with Trimipramine.Approved
VenlafaxineThe serum concentration of Gemcitabine can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Gemcitabine can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Gemcitabine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Gemcitabine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Gemcitabine can be increased when it is combined with Vinorelbine.Approved, Investigational
WarfarinGemcitabine may increase the anticoagulant activities of Warfarin.Approved
ZimelidineThe serum concentration of Gemcitabine can be increased when it is combined with Zimelidine.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

John A. Weigel, "Process for making gemcitabine hydrochloride." U.S. Patent US6001994, issued May, 1995.

US6001994
General References
  1. Link [Link]
External Links
ATC CodesL01BC05 — Gemcitabine
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (105 KB)
MSDSDownload (69.2 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceDiffuse Intrinsic Pontine Glioma (DIPG)1
0RecruitingTreatmentAdenocarcinoma of the Pancreas1
0RecruitingTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
0RecruitingTreatmentPancreatic Ductal Adenocarcinoma1
0TerminatedTreatmentAdenocarcinoma of the Pancreas1
0Unknown StatusTreatmentPancreatic Adenocarcinoma Locally Advanced / Pancreatic Adenocarcinoma Metastatic / Pancreatic Adenocarcinoma Resectable1
0Unknown StatusTreatmentPancreatic Adenocarcinoma Resectable1
1Active Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
1Active Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage III Pancreatic Cancer1
1Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas1
1Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Pancreatic Adenocarcinoma Metastatic1
1Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Stage III Pancreatic Cancer1
1Active Not RecruitingTreatmentAdult Solid Neoplasm / Pancreatic Acinar Cell Carcinoma / Pancreatic Ductal Adenocarcinoma / Recurrent Pancreatic Carcinoma / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v71
1Active Not RecruitingTreatmentAdult Solid Neoplasm / Recurrent Ovarian Carcinoma / Recurrent Uterine Corpus Carcinoma / Stage III Ovarian Cancer / Stage III Uterine Corpus Cancer / Stage IV Ovarian Cancer / Stage IV Uterine Corpus Cancer1
1Active Not RecruitingTreatmentBile Duct Carcinoma / Carcinoma of Gallbladder / Carcinoma of Intrahepatic and Extra-hepatic Biliary System / Cholangiocarcinomas1
1Active Not RecruitingTreatmentBiliary Tract Cancer1
1Active Not RecruitingTreatmentBladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureteral Cancer / Urethral Cancer1
1Active Not RecruitingTreatmentCancer of the Urethra / Ureteral Cancer / Urethral Cancer / Urethral Neoplasms1
1Active Not RecruitingTreatmentCancer, Breast / Cancer, Ovarian / Carcinoma, Colorectal / Carcinoma, Pancreatic / Melanoma / Non-Small Cell Lung Carcinoma (NSCLC) / Prostate Cancer / Renal Cell Adenocarcinoma / Tumors, Solid1
1Active Not RecruitingTreatmentCancers1
1Active Not RecruitingTreatmentCholangiocellular Carcinoma) (ICC) / Cholangiolar Carcinoma / Intrahepatic Cholangiocarcinoma / Peripheral Cholangiocarcinoma1
1Active Not RecruitingTreatmentColorectal Cancers / Esophageal Cancers / Gastrointestinal Stromal Tumors (GISTs) / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Rectal Carcinoma1
1Active Not RecruitingTreatmentDuct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1Active Not RecruitingTreatmentHepatocellular,Carcinoma / Malignant Neoplasm of Pancreas1
1Active Not RecruitingTreatmentLocally Advanced Malignant Neoplasm1
1Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Peripheral T-Cell Lymphoma (PTCL)1
1Active Not RecruitingTreatmentLymphoma, Solid Tumor1
1Active Not RecruitingTreatmentMale Breast Cancer / Recurrent Breast Cancer / Recurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas5
1Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas / Stage IV Pancreatic Cancer1
1Active Not RecruitingTreatmentMetastatic Cancers / Pancreatic Cancer Metastatic1
1Active Not RecruitingTreatmentNeoplasms, Pancreatic1
1Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v71
1Active Not RecruitingTreatmentPancreatic Cancer Metastatic1
1Active Not RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Carcinoma1
1Active Not RecruitingTreatmentTumors, Solid1
1Active Not RecruitingTreatmentTumors, Solid / Urethral Cancer1
1CompletedNot AvailableNeoplasms1
1CompletedDiagnosticCarcinoma NOS / Non-Small-Cell Lung Carcinoma (NSCLC)1
1CompletedPreventionLeukemias / Multiple Myeloma (MM)1
1CompletedSupportive CareDrug/Agent Toxicity by Tissue/Organ / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Small Cell Carcinoma / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer1
1CompletedTreatmentAdenocarcinoma of the Pancreas4
1CompletedTreatmentAdenocarcinoma of the Pancreas / Advanced Pancreatic Cancer / Pancreatic Cancer Metastatic1
1CompletedTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
1CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
1CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer2
1CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific2
1CompletedTreatmentAdenocarcinoma of the Pancreas / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAdenocarcinomas / Malignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
1CompletedTreatmentAdult Solid Neoplasm / BRCA1 Mutation Carrier / BRCA2 Mutation Carrier1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentAdvanced Gastrointestinal Malignancies / Tumors, Solid1
1CompletedTreatmentAdvanced Incurable Solid Malignancy1
1CompletedTreatmentAdvanced Pancreatic Cancer2
1CompletedTreatmentAdvanced Solid Tumors3
1CompletedTreatmentAdvanced Solid Tumors / Malignant Lymphomas1
1CompletedTreatmentAnaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentBiliary Cancer / Malignant Neoplasm of Pancreas1
1CompletedTreatmentBiliary Cancer / Malignant Neoplasm of Pancreas / Malignant Solid Tumours1
1CompletedTreatmentBiliary Tract Cancer2
1CompletedTreatmentBiliary Tract Neoplasms / Cholangiocarcinomas / Gallbladder Neoplasms1
1CompletedTreatmentBladder Cancers / Cancer, Breast / Cancer, Ovarian / Carcinoma of Unknown Primary / Esophageal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Melanoma (Skin) / Prostate Cancer / Sarcomas1
1CompletedTreatmentBladder Cancers / Cancer, Breast / Colorectal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas / Renal Cancers1
1CompletedTreatmentBladder Cancers / Renal Pelvis Cancer / Ureteral Cancer1
1CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter3
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentCancer, Advanced / Tumors, Solid1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Prostate Cancer / Renal Cancers / Sarcomas1
1CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentCancer, Ovarian / Endometrial Cancers / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentCancers3
1CompletedTreatmentCholangiocarcinoma of the Gallbladder / Localized Gallbladder Cancer / Unresectable Gallbladder Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers / Esophageal Cancers / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer / Lung Cancers / Malignant Lymphomas / Malignant Neoplasm of Pancreas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers / Lung Cancers1
1CompletedTreatmentDuct Cell Adenocarcinoma of the Pancreas / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer / Malignant Neoplasm of Pancreas / Periampullary Adenocarcinoma / Small Intestine Cancer1
1CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Malignant Neoplasm of Pancreas1
1CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Small Intestine Cancer1
1CompletedTreatmentHepatic Complications1
1CompletedTreatmentHistologically or Cytologically Confirmed Pancreatic Ca / Unresectable or Borderline Resectable Pancreatic Ca1
1CompletedTreatmentHodgkins Disease (HD) / Neoplasms / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeiomyosarcomas / Liposarcoma1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Plasma Cell Myeloma1
1CompletedTreatmentLeydig Cell Tumor / Ovarian Sarcoma / Ovarian Stromal Cancer / Pseudomyxoma Peritonei / Recurrent Cervical Cancer / Recurrent Endometrial Carcinoma / Recurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Primary Peritoneal Cavity Cancer / Recurrent Uterine Sarcoma / Recurrent Vaginal Cancer / Recurrent Vulvar Cancer1
1CompletedTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV1
1CompletedTreatmentLung Cancer, Non-Small Cell1
1CompletedTreatmentLung Cancers1
1CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentMalignant Lymphomas1
1CompletedTreatmentMalignant Neoplasm of Pancreas20
1CompletedTreatmentMalignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
1CompletedTreatmentMalignant Neoplasm of Pancreas / Tumors, Solid1
1CompletedTreatmentMalignant Neoplasm of Pancreas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Neoplasmas / Tumors, Solid1
1CompletedTreatmentMalignant Pleural Effusions / Recurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentMalignant Pleural Mesothelioma (MPM)1
1CompletedTreatmentMetastatic Pancreatic Carcinoma1
1CompletedTreatmentMetastatic Solid Tumors1
1CompletedTreatmentNeoplasms5
1CompletedTreatmentNeoplasms Malignant1
1CompletedTreatmentNeoplasms, Gastrointestinal / Neoplasms, Pancreatic1
1CompletedTreatmentNeoplasms, Pancreatic4
1CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
1CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Ovarian Epithelial Cancer1
1CompletedTreatmentPancreatic Cancer Metastatic1
1CompletedTreatmentPancreatic Cancer Metastatic / Pancreatic Carcinoma Non-resectable1
1CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentSarcomas2
1CompletedTreatmentSolid Tumors and Non-Hodgkin's Lymphoma1
1CompletedTreatmentSolid Tumors or Mantle Cell Lymphoma1
1CompletedTreatmentSpecific Advanced Solid Tumors1
1CompletedTreatmentTumors1
1CompletedTreatmentTumors, Solid12
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific20
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Metastatic Malignant Solid Neoplasm1
1Not Yet RecruitingTreatmentCholangiocarcinoma Non-resectable / Cholangiocarcinoma, Extrahepatic / Cholangiocarcinoma, Intrahepatic / Gallbladder Adenocarcinoma1
1Not Yet RecruitingTreatmentMalignant Neoplasm of Male Genital Organs / Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma / Malignant Neoplasms of Bone and Articular Cartilage / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Mesothelial and Soft Tissue / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract / Melanoma and Other Malignant Neoplasms of Skin1
1Not Yet RecruitingTreatmentNon-Resectable Cholangiocarcinoma / Recurrent Cholangiocarcinoma / Stage III Extrahepatic Bile Duct Cancer / Stage III Intrahepatic Cholangiocarcinoma / Stage IIIA Hilar Cholangiocarcinoma / Stage IIIB Hilar Cholangiocarcinoma / Stage IVA Extrahepatic Bile Duct Cancer / Stage IVA Hilar Cholangiocarcinoma / Stage IVA Intrahepatic Cholangiocarcinoma / Stage IVB Extrahepatic Bile Duct Cancer / Stage IVB Hilar Cholangiocarcinoma / Stage IVB Intrahepatic Cholangiocarcinoma / Unresectable Extrahepatic Bile Duct Carcinoma1
1Not Yet RecruitingTreatmentPancreatic Cancer Stage III / Pancreatic Cancer Stage IV1
1RecruitingNot AvailableMalignant Neoplasm of Pancreas1
1RecruitingNot AvailablePancreatic Cancer Metastatic1
1RecruitingBasic ScienceSoft Tissue Sarcoma Adult1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Adult Solid Neoplasm / Advanced Malignant Solid Neoplasm / ALK positive / Pancreatic Adenocarcinoma Metastatic / Solid Neoplasms / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1RecruitingTreatmentAbdominal wall neoplasm / Carcinoma, Squamous Cell of Head and Neck / Esophagogastric Junction Neoplasms / Fallopian Tube Neoplasms / Neoplasms, Ovarian / Small Cell Lung Carcinoma / Stomach Neoplasms / Triple Negative Breast Neoplasms1
1RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Adenocarcinoma of the Gallbladder / Adult Primary Cholangiocellular Carcinoma / Advanced Adult Primary Liver Cancer / Cholangiocarcinoma of the Gallbladder / Duct Cell Adenocarcinoma of the Pancreas / Localized Unresectable Adult Primary Liver Cancer / Periampullary Adenocarcinoma / Recurrent Adult Primary Liver Cancer / Recurrent Gallbladder Cancer / Recurrent Pancreatic Cancer / Stage II Gallbladder Cancer / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIB Gallbladder Cancer / Stage IV Pancreatic Cancer / Stage IVA Gallbladder Cancer / Stage IVB Gallbladder Cancer1
1RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Head and Neck Squamous Cell Carcinoma (HNSCC) / Non-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma Metastatic / Recurrent Gallbladder Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Gallbladder Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Unresectable Gallbladder Carcinoma / Unresectable Pancreatic Cancer1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Locally Advanced Solid Tumors / Metastatic Solid Tumors1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Pancreatic Adenocarcinoma Metastatic / Stage IV Pancreatic Cancer / Unresectable Pancreatic Carcinoma1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
1RecruitingTreatmentAdvanced Solid Tumors1
1RecruitingTreatmentAdvanced Solid Tumors / Malignant Lymphomas / Tumors, Solid1
1RecruitingTreatmentAdvanced Solid Tumors / Malignant Neoplasm of Pancreas / Tumors, Solid1
1RecruitingTreatmentBiliary Tract Carcinoma / Cancer, Advanced / Cholangiocarcinomas / Gall Bladder Carcinoma / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL) / Tumors, Solid1
1RecruitingTreatmentBladder Cancers1
1RecruitingTreatmentBorderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy / Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy1
1RecruitingTreatmentCancer of Pancreas / Cancer of the Pancreas / Malignant Neoplasm of Pancreas1
1RecruitingTreatmentCancer, Advanced1
1RecruitingTreatmentCancer, Advanced Solid Tumors1
1RecruitingTreatmentCancer, Advanced / Colorectal Cancers / Metastatic Melanoma / Metastatic Non-Small Cell Lung Cancer / Metastatic Pancreatic Ductal Adenocarcinoma1
1RecruitingTreatmentCancer, Breast / Cholangiocarcinomas / Malignant Neoplasm of Colon / Soft Tissue Sarcoma (STS) / Tumors, Solid1
1RecruitingTreatmentCancer, Breast / Colorectal Cancers / Esophagogastric Cancer / Malignant Neoplasm of Pancreas / Non-Small-Cell Lung Carcinoma (NSCLC) / Tumors1
1RecruitingTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
1RecruitingTreatmentCholangiocarcinomas / Neoplasms, Hepatic1
1RecruitingTreatmentEstrogen Receptor Negative / Folate Receptor Alpha Positive / HER2/Neu Negative / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Uterine Corpus Carcinoma / Triple-Negative Breast Carcinoma1
1RecruitingTreatmentHodgkins Disease (HD) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, T-Cell, Cutaneous / Lymphoma, T-Cell, Peripheral1
1RecruitingTreatmentLymphoma, B-Cell1
1RecruitingTreatmentMalignant Neoplasm of Pancreas8
1RecruitingTreatmentMalignant Neoplasm of Pancreas / Stage IV Pancreatic Cancer1
1RecruitingTreatmentMetastatic Urothelial Carcinoma of the Renal Pelvis and Ureter / Recurrent Bladder Carcinoma / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter / Stage III Bladder Urothelial Carcinoma / Stage III Urethral Cancer / Stage IV Bladder Urothelial Carcinoma / Stage IV Urethral Cancer / Urethral Urothelial Carcinoma1
1RecruitingTreatmentNasopharyngeal Carcinoma2
1RecruitingTreatmentNeoplasms2
1RecruitingTreatmentNeoplasms, Breast / Neoplasms, Pancreatic1
1RecruitingTreatmentNeoplasms, Malignant / Tumors, Solid1
1RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Solid Neoplasms / Stage IV Pancreatic Cancer1
1RecruitingTreatmentPancreatic Ductal Adenocarcinoma / Sarcomas1
1RecruitingTreatmentRecurrent Non-small Cell Lung Cancer1
1RecruitingTreatmentSarcoma, Bone / Sarcomas / Soft Tissue Sarcoma (STS)1
1RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentUrothelial Carcinoma of the Urinary Bladder1
1SuspendedTreatmentBile Duct Carcinoma1
1SuspendedTreatmentBiliary Tract Carcinoma / Carcinoma of Gallbladder1
1TerminatedTreatmentAdenocarcinoma of the Pancreas1
1TerminatedTreatmentAdenocarcinoma of the Pancreas / Refractory Solid Tumors1
1TerminatedTreatmentAdult Solid Neoplasm1
1TerminatedTreatmentAdvanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Stage III Pancreatic Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Bladder Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Transitional Cell Carcinoma of the Bladder / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
1TerminatedTreatmentAdvanced Aggressive Non-Hodgkin's Lymphoma / Advanced Hodgkin's Lymphoma / Advanced Indolent Non-Hodgkin's Lymphoma / Advanced Pancreatic Adenocarcinoma / Advanced Solid Tumors / Advanced Triple-Negative Breast Cancer / Advanced Urothelial Carcinoma1
1TerminatedTreatmentAdvanced Solid Malignancies / Cancers / Tumors, Solid2
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentCancer, Breast / Colorectal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas1
1TerminatedTreatmentCancer, Ovarian / Carcinoma NOS / Neoplasms, Ovarian / Ovarian Diseases1
1TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1TerminatedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
1TerminatedTreatmentCancers / Malignant Lymphomas1
1TerminatedTreatmentCancers / Solid Cancers1
1TerminatedTreatmentCholestasis / Neoplasms, Pancreatic1
1TerminatedTreatmentEsophageal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas1
1TerminatedTreatmentExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentFallopian Tube Neoplasms / Neoplasms / Neoplasms, Ovarian / Primary Peritoneal Neoplasms1
1TerminatedTreatmentHead and Neck Carcinoma1
1TerminatedTreatmentHodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL)1
1TerminatedTreatmentInoperable Locally Advanced or Metastatic Biliary Tract Cancer1
1TerminatedTreatmentLung Cancers1
1TerminatedTreatmentMalignant Lymphomas1
1TerminatedTreatmentMalignant Lymphomas / Solid Neoplasms1
1TerminatedTreatmentMalignant Neoplasm of Pancreas6
1TerminatedTreatmentMeningitis / Neoplasms1
1TerminatedTreatmentMetastatic Adenocarcinoma of the Pancreas1
1TerminatedTreatmentMetastatic Disease1
1TerminatedTreatmentNeoplasms2
1TerminatedTreatmentNeoplasms, Pancreatic3
1TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1TerminatedTreatmentPancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection1
1TerminatedTreatmentTumors, Solid1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusTreatmentCervical Carcinoma1
1Unknown StatusTreatmentHead and Neck Carcinoma1
1Unknown StatusTreatmentLung Cancers / Lymphoproliferative Disorders / Malignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusTreatmentLymphoma, Hodgkins1
1Unknown StatusTreatmentMalignant Neoplasm of Pancreas3
1Unknown StatusTreatmentMalignant Neoplasm of Pancreas / Pancreatic Adenocarcinoma Metastatic / Pancreatic Cancer Metastatic1
1Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific3
1WithdrawnTreatmentAdult Solid Neoplasm / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1WithdrawnTreatmentBladder Cancers1
1WithdrawnTreatmentDuct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnTreatmentMuscle-invasive Transitional Cell Carcinoma of the Bladder1
1WithdrawnTreatmentNon-Small Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC) / Nonsmall Cell Lung Cancer / Tumors, Solid1
1WithdrawnTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer1
1WithdrawnTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
1, 2Active Not RecruitingTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
1, 2Active Not RecruitingTreatmentAdvanced Biliary Tract Carcinoma1
1, 2Active Not RecruitingTreatmentAdvanced Cancers / Malignant Lymphomas1
1, 2Active Not RecruitingTreatmentCancer, Advanced / Cancer, Breast / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Pancreas / Ovarian / Sarcomas1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
1, 2Active Not RecruitingTreatmentHepatic Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas1
1, 2Active Not RecruitingTreatmentMalignant Tumor of Renal Pelvis / Transitional Cell Carcinoma of Bladder / Ureteral Cancer / Urethral Cancer1
1, 2Active Not RecruitingTreatmentMetastatic Cancers1
1, 2Active Not RecruitingTreatmentNon-muscle Invasive Bladder Cancer (NMIBC)1
1, 2Active Not RecruitingTreatmentPancreatic Acinar Cell Carcinoma / Pancreatic Adenocarcinoma Metastatic / Pancreatic Ductal Adenocarcinoma / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v7 / Unresectable Pancreatic Carcinoma1
1, 2Active Not RecruitingTreatmentPancreatic Cancer, Adult1
1, 2Active Not RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Refractory Childhood Hodgkin Lymphoma1
1, 2Active Not RecruitingTreatmentRenal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2Active Not RecruitingTreatmentResectable Pancreatic Adenocarcinoma1
1, 2Active Not RecruitingTreatmentSquamous Non-Small Cell Lung Cancer1
1, 2CompletedTreatmentAdenocarcinoma of the Pancreas2
1, 2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
1, 2CompletedTreatmentAdenocarcinomas / Neoplasms, Pancreatic1
1, 2CompletedTreatmentAdvanced Soft Tissue Sarcoma1
1, 2CompletedTreatmentBiliary Tract Cancer1
1, 2CompletedTreatmentBiliary Tract Cancer / Cholangiocarcinomas / Gallbladder Cancer1
1, 2CompletedTreatmentBladder Cancers3
1, 2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
1, 2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentCancer, Ovarian1
1, 2CompletedTreatmentCarcinoma, Pancreatic1
1, 2CompletedTreatmentCholangiocarcinomas1
1, 2CompletedTreatmentCholangiocellular Carcinoma1
1, 2CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
1, 2CompletedTreatmentHodgkins Disease (HD)1
1, 2CompletedTreatmentLocally Advanced Pancreatic Cancer / Pancreatic Cancer Metastatic1
1, 2CompletedTreatmentLocally Advanced Sarcoma / Metastatic Sarcoma / Sarcomas / Soft Tissue Sarcoma (STS) / Unresectable Sarcoma1
1, 2CompletedTreatmentLocally Advanced and Metastatic Pancreatic Cancer1
1, 2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1, 2CompletedTreatmentLung Cancers4
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Hodgkins / Peripheral T-Cell Lymphoma (PTCL) / Relapsed or Refractory Lymphoproliferative Malignancies / Waldenstrom's Macroglobulinemia (WM)1
1, 2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMalignant Neoplasm of Pancreas9
1, 2CompletedTreatmentMalignant Neoplasm of Pancreas / Neoplasms / Neoplasms Metastasis1
1, 2CompletedTreatmentMetastatic Cancers / Pancreatic Cancer Metastatic1
1, 2CompletedTreatmentNeoplasms, Gastrointestinal / Neoplasms, Ovarian1
1, 2CompletedTreatmentNeoplasms, Lung1
1, 2CompletedTreatmentNeoplasms, Pancreatic3
1, 2CompletedTreatmentNeoplasms / Neoplasms, Pancreatic1
1, 2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentOperable Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma1
1, 2CompletedTreatmentPancreatic Cancer Metastatic2
1, 2CompletedTreatmentProstate Cancer1
1, 2CompletedTreatmentRecurrent Bladder Carcinoma / Stage II Bladder Cancer / Stage III Bladder Cancer / Stage IV Bladder Cancer1
1, 2CompletedTreatmentRecurrent Breast Carcinoma / Stage IV Breast Cancer1
1, 2CompletedTreatmentStage IV Pancreatic Cancer4
1, 2CompletedTreatmentTransitional Cell Carcinoma1
1, 2CompletedTreatmentTumors1
1, 2CompletedTreatmentUterine Cervical Cancer2
1, 2Not Yet RecruitingOtherSarcomas1
1, 2Not Yet RecruitingTreatmentMalignant Lymphomas / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
1, 2Not Yet RecruitingTreatmentMature T-Cell and NK-Cell Neoplasm1
1, 2RecruitingBasic ScienceCancer, Breast / Cancer, Ovarian / Colorectal Cancers / Malignant Neoplasm of Colon / Neoplasms / Rectal Carcinoma / Tumors, Solid1
1, 2RecruitingTreatmentAdenocarcinoma of the Pancreas3
1, 2RecruitingTreatmentAdenocarcinomas of the Pancreas1
1, 2RecruitingTreatmentAdvanced Adenocarcinoma / Metastatic Adenocarcinoma1
1, 2RecruitingTreatmentAdvanced Biliary Tract Malignant Tumor1
1, 2RecruitingTreatmentAdvanced Pancreatic Cancer1
1, 2RecruitingTreatmentAdvanced or Metastatic Colorectal Cancer (CRC) / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor / Advanced or Metastatic Solid Tumors / Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous) / Pancreatic Ductal Adenocarcinoma (PDAC)1
1, 2RecruitingTreatmentBiliary Tract Cancer1
1, 2RecruitingTreatmentBladder Cancers1
1, 2RecruitingTreatmentBladder Cancers / Metastatic Bladder Cancer / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentCancer, Advanced1
1, 2RecruitingTreatmentCancer, Breast / Cholangiocarcinomas / Malignant Solid Tumours / MPN / Multiple Myeloma (MM) / Neoplasms, Endometrial / Non-Small-Cell Lung Carcinoma (NSCLC) / Stomach Neoplasms / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentCholangiocarcinomas2
1, 2RecruitingTreatmentColorectal Cancers / Malignant Neoplasm of Pancreas1
1, 2RecruitingTreatmentDigestive Cancers1
1, 2RecruitingTreatmentFollicular Lymphoma (FL) / Hodgkin's Lymphoma - Relapsed/Refractory / Non-Hodgkin's Lymphoma - Aggressive1
1, 2RecruitingTreatmentHigh Grade Ovarian Serous Adenocarcinoma / Ovarian Endometrioid Tumor / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer1
1, 2RecruitingTreatmentLeukemias1
1, 2RecruitingTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2RecruitingTreatmentMalignant Lymphomas2
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas2
1, 2RecruitingTreatmentMetastatic Pancreatic Ductal Adenocarcinoma1
1, 2RecruitingTreatmentNeoplasms, Gastrointestinal1
1, 2RecruitingTreatmentNeoplasms, Pancreatic1
1, 2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
1, 2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic4
1, 2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Pancreatic Cancer Metastatic1
1, 2RecruitingTreatmentPancreatic Cancer (Unresectable)1
1, 2RecruitingTreatmentPancreatic Cancer Metastatic1
1, 2RecruitingTreatmentPancreatic Ductal Carcinoma1
1, 2RecruitingTreatmentPancreatic Neoplasms (Locally Advanced Non-metastatic)1
1, 2RecruitingTreatmentSarcomas1
1, 2RecruitingTreatmentSoft Tissue Sarcoma (STS)1
1, 2RecruitingTreatmentTumors, Solid1
1, 2SuspendedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage IV Pancreatic Cancer1
1, 2SuspendedTreatmentMalignant Neoplasm of Pancreas1
1, 2SuspendedTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1, 2TerminatedTreatmentCancer, Ovarian1
1, 2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer1
1, 2TerminatedTreatmentCancers / Carcinoma, Pancreatic / Malignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentHistiocytoma/Undifferentiated Pleomorphic Sarcoma / Leiomyosarcomas / Malignant Fibrous / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Sarcomas1
1, 2TerminatedTreatmentLung Cancers2
1, 2TerminatedTreatmentMalignant Lymphomas1
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas4
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Ductal Adenocarcinoma1
1, 2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
1, 2TerminatedTreatmentNeoplasms1
1, 2TerminatedTreatmentNeoplasms, Malignant1
1, 2TerminatedTreatmentPancreatic Cancer Metastatic1
1, 2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
1, 2Unknown StatusTreatmentColorectal Cancers2
1, 2Unknown StatusTreatmentHead and Neck Carcinoma1
1, 2Unknown StatusTreatmentMalignant Neoplasm of Pancreas2
1, 2Unknown StatusTreatmentStage IV Pancreatic Cancer1
1, 2Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2WithdrawnTreatmentCancer, Ovarian1
1, 2WithdrawnTreatmentMalignant Lymphomas1
1, 2WithdrawnTreatmentMalignant Neoplasm of Pancreas1
1, 2WithdrawnTreatmentPancreatic Cancer, Metastatic1
2Active Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of Ampulla / Ductal Adenocarcinoma of Pancreas1
2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas1
2Active Not RecruitingTreatmentAdult T-cell lymphomas/leukaemias1
2Active Not RecruitingTreatmentAdvanced Biliary Tract Cancer(BTC)1
2Active Not RecruitingTreatmentAdvanced Malignant Pleural Mesothelioma1
2Active Not RecruitingTreatmentBiliary Cancer / Cholangiocarcinomas1
2Active Not RecruitingTreatmentBiliary Tract Cancer3
2Active Not RecruitingTreatmentBiliary Tract Cancer / Cancer, Advanced / Metastatic Cancers1
2Active Not RecruitingTreatmentBladder Cancers3
2Active Not RecruitingTreatmentBladder Cancers / Urachal Cancer / Urethral Cancer1
2Active Not RecruitingTreatmentCancer, Breast2
2Active Not RecruitingTreatmentCancer, Ovarian1
2Active Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer1
2Active Not RecruitingTreatmentCancers1
2Active Not RecruitingTreatmentCholangiocarcinomas3
2Active Not RecruitingTreatmentDistal Urethral Cancer / Proximal Urethral Cancer / Squamous Cell Carcinoma of the Bladder / Stage II Bladder Cancer / Stage III Bladder Cancer / Urethral Cancer Associated With Invasive Bladder Cancer1
2Active Not RecruitingTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer1
2Active Not RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2Active Not RecruitingTreatmentFocus of Study Instead1
2Active Not RecruitingTreatmentHead and Neck Carcinoma1
2Active Not RecruitingTreatmentLeiomyosarcomas1
2Active Not RecruitingTreatmentLung Cancers1
2Active Not RecruitingTreatmentLymphoma, Mantle-Cell / Mantle Cell Lymphoma (MCL)1
2Active Not RecruitingTreatmentMalignant Lymphomas2
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas17
2Active Not RecruitingTreatmentMesothelioma, Malignant1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentMetastatic HER2-Positive Breast Cancer1
2Active Not RecruitingTreatmentMetastatic Leiomyosarcoma1
2Active Not RecruitingTreatmentMetastatic Pancreatic Ductal Adenocarcinoma1
2Active Not RecruitingTreatmentMetastatic Sarcoma1
2Active Not RecruitingTreatmentMetastatic Ureteral Neoplasm / Metastatic Urethral Neoplasm / Stage III Bladder Urothelial Carcinoma / Stage III Ureter Cancer / Stage III Urethral Cancer / Stage IV Bladder Urothelial Carcinoma / Stage IV Ureter Cancer / Stage IV Urethral Cancer / Ureter Urothelial Carcinoma / Urethral Urothelial Carcinoma1
2Active Not RecruitingTreatmentNeoplasms, Ovarian / Ovarian Cancer (OvCa) / Ovarian Epithelial Cancer1
2Active Not RecruitingTreatmentNeoplasms, Pancreatic1
2Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)4
2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic3
2Active Not RecruitingTreatmentPancreatic Cancer Metastatic6
2Active Not RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2Active Not RecruitingTreatmentPlasma Cell Myeloma1
2Active Not RecruitingTreatmentRecurrent Pancreatic Carcinoma / Stage IV Pancreatic Cancer1
2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of Lung1
2Active Not RecruitingTreatmentTransitional Cell Carcinoma1
2Active Not RecruitingTreatmentUrinary Bladder1
2CompletedNot AvailableBladder Cancers1
2CompletedNot AvailableNon-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedPreventionPancreatic Cancer Metastatic1
2CompletedSupportive CareCancers / Chemotherapy-Induced Thrombocytopenia / Lung Cancers / Neoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Oncology / Thrombocytopenias / Tumors, Solid1
2CompletedTreatmentAbdominal wall neoplasm / Ovarian Carcinoma1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of Gallbladder / Cholangiocarcinomas1
2CompletedTreatmentAdenocarcinoma of the Pancreas1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer2
2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer3
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage III Pancreatic Cancer / Stage IVA Pancreatic Cancer1
2CompletedTreatmentAdenocarcinomas3
2CompletedTreatmentAdenocarcinomas / Metastasis / Pancreas Neoplasms1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAdvanced Biliary Tract Adenocarcinoma / Combination Chemotherapy / Efficacy / Gemcitabine / Oxaliplatin1
2CompletedTreatmentAdvanced Colorectal Cancer1
2CompletedTreatmentAdvanced Malignant Mesothelioma / Epithelial Mesothelioma / Localized Malignant Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma1
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer2
2CompletedTreatmentAdvanced Pancreatic Carcinoma1
2CompletedTreatmentAmpullary Cancer / Cholangiocarcinoma Cancer / Gallbladder Cancer / Malignant Neoplasm of Pancreas1
2CompletedTreatmentAmpullary Carcinoma / Biliary Tract Cancer / Cancer Of The Extrahepatic Bile Duct / Gallbladder Cancer1
2CompletedTreatmentAnxiety Disorder / Depressive State / Lung Cancers / Tiredness1
2CompletedTreatmentBiliary Cancer / Malignant Neoplasm of Pancreas1
2CompletedTreatmentBiliary Carcinoma1
2CompletedTreatmentBiliary Tract Cancer2
2CompletedTreatmentBiliary Tract Cancer / Gallbladder Adenocarcinoma1
2CompletedTreatmentBiliary Tract Cancer / Gallbladder Cancer2
2CompletedTreatmentBiliary Tract Carcinoma1
2CompletedTreatmentBiliary Tract Neoplasms1
2CompletedTreatmentBiliary Tract Neoplasms / Neoplasms, Pancreatic1
2CompletedTreatmentBladder Cancers11
2CompletedTreatmentBladder Cancers / Drug/Agent Toxicity by Tissue/Organ1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter2
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer6
2CompletedTreatmentBladder Cancers / Urethral Cancer1
2CompletedTreatmentBladder Cancers / Urinary Bladder1
2CompletedTreatmentBladder Transitional Cell Carcinoma Stage IV1
2CompletedTreatmentBreast Cancer, Metastatic1
2CompletedTreatmentCachexia / Neoplasms, Pancreatic1
2CompletedTreatmentCancer of Cervix1
2CompletedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancer of the Pancreatic Head1
2CompletedTreatmentCancer, Breast30
2CompletedTreatmentCancer, Breast / Locally Advanced / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancer, Breast / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentCancer, Ovarian3
2CompletedTreatmentCancer, Ovarian / Cervical Cancers / Endometrial Cancers1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Neoplasms, Ovarian / Peritoneal Cancer1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer2
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Ovarian / Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cancer1
2CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Ovarian / Sarcomas / Small Intestine Cancer1
2CompletedTreatmentCancer, Ovarian / Testicular germ cell tumour1
2CompletedTreatmentCancers1
2CompletedTreatmentCancers / Myeloproliferative Disorders / Transitional Cell Carcinoma1
2CompletedTreatmentCarboplatin Adverse Reaction / Lung Cancers1
2CompletedTreatmentCarcinoma of Unknown Primary1
2CompletedTreatmentCarcinoma of Unknown Primary / Pain1
2CompletedTreatmentCarcinoma, Non-Small-Cell Lung (NSCLC)1
2CompletedTreatmentCarcinoma, Non-Small-Cell-Lung Cancer1
2CompletedTreatmentCholangiocarcinomas3
2CompletedTreatmentCholangiocarcinomas / Gallbladder Cancer1
2CompletedTreatmentColorectal Cancers3
2CompletedTreatmentColorectal Cancers / Malignant Neoplasm of Colon1
2CompletedTreatmentDistal Urethral Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Proximal Urethral Cancer / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Urethral Cancer Associated With Invasive Bladder Cancer1
2CompletedTreatmentDuct Cell Adenocarcinoma of the Pancreas / Stage IV Pancreatic Cancer1
2CompletedTreatmentDuctal Adrenocarcinoma / Exocrine Pancreatic Cancer / Malignant Neoplasm of Pancreas1
2CompletedTreatmentEfficacy / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Recurrent Uterine Corpus Carcinoma1
2CompletedTreatmentEndometrial Cancers2
2CompletedTreatmentEsophageal Cancers1
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer3
2CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
2CompletedTreatmentGenital Neoplasms, Male1
2CompletedTreatmentGerm Cell Neoplasms / Testicular Cancer1
2CompletedTreatmentHead and Neck Carcinoma8
2CompletedTreatmentHemangiosarcoma / Histiocytoma / Leiomyosarcomas / Malignant Fibrous / Sarcomas1
2CompletedTreatmentHepatocellular,Carcinoma2
2CompletedTreatmentHodgkins Disease (HD)2
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Hodgkin Disease / Lymphoma, Hodgkins / Malignant Lymphomas1
2CompletedTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)2
2CompletedTreatmentLeiomyosarcomas / Uterine Neoplasms1
2CompletedTreatmentLeukemias3
2CompletedTreatmentLiver Cancer2
2CompletedTreatmentLocally Advanced Breast Cancer (LABC) / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentLocally Advanced Pancreatic Cancer / Nonmetastatic Pancreatic Cancer / Patients With Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer / Unresectable Pancreatic Cancer1
2CompletedTreatmentLocally Advanced Pancreatic Cancer / Pancreatic Cancer Metastatic1
2CompletedTreatmentLocally Advanced / Metastatic / Unresectable1
2CompletedTreatmentLung Cancers32
2CompletedTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentLymphoma, Large Cell, Diffuse1
2CompletedTreatmentMalignant Gastrointestinal Stromal Tumor / Sarcomas1
2CompletedTreatmentMalignant Lymphomas11
2CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer1
2CompletedTreatmentMalignant Neoplasm of Nasopharynx1
2CompletedTreatmentMalignant Neoplasm of Pancreas62
2CompletedTreatmentMalignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
2CompletedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Cancer Metastatic1
2CompletedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Diseases / Pancreatic Ductal Carcinoma2
2CompletedTreatmentMalignant Neoplasm of Pancreas / Thromboembolism1
2CompletedTreatmentMalignant Pleural Effusions / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentMalignant Solid Tumours1
2CompletedTreatmentMesothelioma2
2CompletedTreatmentMesothelioma, Malignant3
2CompletedTreatmentMetastatic Bladder Cancer / Urinary Tract Neoplasms / Urologic Neoplasms1
2CompletedTreatmentMetastatic Breast Cancer (MBC)10
2CompletedTreatmentMetastatic Carcinoma / Recurrent Esophageal Squamous Cell Carcinoma1
2CompletedTreatmentMetastatic Colorectal Cancers2
2CompletedTreatmentMetastatic Non-Small Cell Lung Cancer / Non-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentMetastatic Renal Cell Carcinoma1
2CompletedTreatmentMetastatic Renal Cell Carcinoma / Renal Cell Carcinoma With Sarcomatoid Features1
2CompletedTreatmentMetastatic Soft Tissue Sarcoma1
2CompletedTreatmentMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Squamous Cell Carcinoma of the Bladder / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
2CompletedTreatmentMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter1
2CompletedTreatmentMetastatic or Recurrent Colorectal Cancer / Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan / Salvage Chemotherapy1
2CompletedTreatmentMetastatic / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentMixed Mullerian Tumors of the Uterus1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentNasopharyngeal Carcinoma1
2CompletedTreatmentNasopharyngeal Neoplasms1
2CompletedTreatmentNasopharyngeal Squamous Cell Carcinoma / Toxicity Due to Radiotherapy1
2CompletedTreatmentNeoplasm Metastases / Renal Cell Adenocarcinoma1
2CompletedTreatmentNeoplasm, Bladder1
2CompletedTreatmentNeoplasms Metastasis / Neoplasms, Pancreatic1
2CompletedTreatmentNeoplasms, Breast3
2CompletedTreatmentNeoplasms, Lung1
2CompletedTreatmentNeoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Pulmonary Neoplasms1
2CompletedTreatmentNeoplasms, Ovarian1
2CompletedTreatmentNeoplasms, Pancreatic8
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)4
2CompletedTreatmentNon-Hodgkin's Lymphoma (CD20+)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)37
2CompletedTreatmentNon-Small-Cell-Lung Cancer (NSCLC)1
2CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer3
2CompletedTreatmentOvarian Epithelial Cancer1
2CompletedTreatmentPancreas Neoplasms1
2CompletedTreatmentPancreatic Adenocarcinoma Metastatic2
2CompletedTreatmentPancreatic Cancer Metastatic8
2CompletedTreatmentPancreatic Cancer Stage IVA1
2CompletedTreatmentPrimary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRecurrent Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
2CompletedTreatmentRecurrent Nasopharyngeal Cancer / Stage IV Nasopharyngeal Cancer1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer1
2CompletedTreatmentRecurrent Uterine Corpus Sarcoma / Uterine Carcinosarcoma1
2CompletedTreatmentRecurrent Uterine Corpus Sarcoma / Uterine Corpus Leiomyosarcoma1
2CompletedTreatmentRefractory Aggressive Non-Hodgkin's Lymphoma / Relapsing Aggressive Non-Hodgkin's Lymphoma1
2CompletedTreatmentRelapsed or Refractory Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentRenal Cancers5
2CompletedTreatmentRenal Cancers / Renal Cell Adenocarcinoma1
2CompletedTreatmentRenal Cell Adenocarcinoma1
2CompletedTreatmentResectable Pancreatic Cancers1
2CompletedTreatmentSarcomas3
2CompletedTreatmentSoft Tissue Sarcoma (STS)2
2CompletedTreatmentStage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
2CompletedTreatmentStage II Gallbladder Cancer / Stage IIIA Gallbladder Cancer / Stage IIIB Gallbladder Cancer / Stage IVA Gallbladder Cancer / Stage IVB Gallbladder Cancer1
2CompletedTreatmentStage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer2
2CompletedTreatmentStage IV Pancreatic Cancer1
2CompletedTreatmentSuperficial Bladder Cancer2
2CompletedTreatmentTHE Efficacy and Safety of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer1
2CompletedTreatmentTime to Progression1
2CompletedTreatmentTransitional Cell Carcinoma1
2CompletedTreatmentTransitional Cell Carcinoma / Urologic Neoplasms1
2CompletedTreatmentUnknown Primary Neoplasms1
2CompletedTreatmentUrinary Tract Cancers1
2CompletedTreatmentUrologic Neoplasms2
2CompletedTreatmentUrothelial Cancer1
2CompletedTreatmentFunctional disorders of the biliary tract1
2Enrolling by InvitationTreatmentBorderline Resectable Pancreatic Cancer1
2Not Yet RecruitingOtherUpper Tract Urothelial Carcinoma1
2Not Yet RecruitingTreatmentAdenocarcinoma Metastatic / Adenocarcinoma of the Biliary Tract / Adenocarinoma Locally Advanced / Biliary Tract Cancer / Extrahepatic Bile Duct Carcinoma / Intrahepatic Cholangiocarcinoma / Non-Resectable Hepatocellular Carcinoma1
2Not Yet RecruitingTreatmentAdenocarcinomas / Cancer of Pancreas / Cancer of the Pancreas / Malignant Neoplasm of Pancreas / Neoplasms, Pancreatic / Pancreas Neoplasms1
2Not Yet RecruitingTreatmentBiliary Tract Cancer / Cancer, Advanced / Gallbladder Cancer / Metastatic Cancers1
2Not Yet RecruitingTreatmentBiliary Tract Cancer / Capecitabine / Chemotherapy, Adjuvant / Cholangiocarcinomas / Cisplatin / Gemcitabine1
2Not Yet RecruitingTreatmentCarcinoma, Pancreatic1
2Not Yet RecruitingTreatmentEGFR Gene Mutations / Nonsmall Cell Lung Cancer1
2Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Pancreas / Pancreatic Ductal Adenocarcinoma1
2Not Yet RecruitingTreatmentMetastatic Adenocarcinoma of the Pancreas / Recurrent Adenocarcinoma of the Pancreas1
2Not Yet RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Not Yet RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Not Yet RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
2Not Yet RecruitingTreatmentPancreatic Cancer Metastatic1
2Not Yet RecruitingTreatmentRecurrent and Metastatic Nasopharyngeal Carcinoma1
2Not Yet RecruitingTreatmentTransitional Cell Carcinoma1
2Not Yet RecruitingTreatmentUnresectable Intrahepatic Cholangiocarcinoma1
2RecruitingDiagnosticPancreatic Cancer Metastatic1
2RecruitingDiagnosticStage IIIA Non-Small Cell Lung Cancer1
2RecruitingTreatmentAdenocarcinoma of the Pancreas4
2RecruitingTreatmentAdenocarcinoma of the Pancreas / BRCA1 Mutation Carrier / BRCA2 Mutation Carrier / PALB2 Gene Mutation / Pancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v71
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Pancreatic Cancer Metastatic1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Resectable Pancreatic Carcinoma1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Resectable Pancreatic Carcinoma / Stage I Pancreatic Cancer / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage II Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Unresectable Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinomas1
2RecruitingTreatmentAdult Alveolar Soft Part Sarcoma / Adult Angiosarcoma / Adult Desmoplastic Small Round Cell Tumor / Adult Epithelioid Hemangioendothelioma / Adult Epithelioid Sarcoma / Adult Extraskeletal Myxoid Chondrosarcoma / Adult Extraskeletal Osteosarcoma / Adult Fibrosarcoma / Adult Leiomyosarcoma / Adult Liposarcoma / Adult Malignant Mesenchymoma / Adult Malignant Peripheral Nerve Sheath Tumor / Adult Rhabdomyosarcoma / Adult Synovial Sarcoma / Adult Undifferentiated Pleomorphic Sarcoma / Malignant Adult Hemangiopericytoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2RecruitingTreatmentAdvanced Breast Cancer1
2RecruitingTreatmentAdvanced Triple Negative Breast Cancer (TNBC) With High TAMs1
2RecruitingTreatmentAggressive Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL)1
2RecruitingTreatmentAmyloidosis / Multiple Myeloma (MM)1
2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2RecruitingTreatmentBiliary Cancer1
2RecruitingTreatmentBiliary Carcinoma / Carcinoma of Gallbladder / Cholangiocarcinomas1
2RecruitingTreatmentBiliary Carcinoma / Cholangiocarcinomas / Gall Bladder Carcinoma / Gastrointestinal Tumors1
2RecruitingTreatmentBiliary Tract Cancer1
2RecruitingTreatmentBiliary Tract Carcinoma / Carcinoma of Gallbladder1
2RecruitingTreatmentBiliary Tract Neoplasms2
2RecruitingTreatmentBladder Cancers2
2RecruitingTreatmentBladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureteral Cancer / Urethral Cancer1
2RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma1
2RecruitingTreatmentBorderline Resectable Pancreatic Cancer1
2RecruitingTreatmentBorderline Resectable Pancreatic Cancer / Pancreas Neoplasm Malignant Resectable1
2RecruitingTreatmentBreast Cancer Metastatic1
2RecruitingTreatmentCNS Germ Cell Tumor1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentCancer, Breast / Neoplasms, Breast / Triple-Negative Breast Cancer (TNBC) / Triple-Negative Breast Neoplasms1
2RecruitingTreatmentCancer, Ovarian1
2RecruitingTreatmentCholangiocellular Carcinoma / Cholangiolar Carcinoma / Intrahepatic Cholangiocarcinoma / Peripheral Cholangiocarcinoma1
2RecruitingTreatmentDuctal Adenocarcinoma of the Pancreas / Resectable Pancreatic Cancers1
2RecruitingTreatmentEGFR Activating Mutation / Metastatic Non-Small Cell Lung Cancer1
2RecruitingTreatmentEGFR Gene Mutations / Non-Small Cell Lung Carcinoma (NSCLC)1
2RecruitingTreatmentEwing's Sarcoma (ES) / Rhabdomyosarcomas / Sarcoma, Osteogenic / Soft Tissue Sarcoma (STS)1
2RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2RecruitingTreatmentFallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Clear Cell Tumor / Malignant Ovarian Endometrioid Tumor / Malignant Ovarian Mixed Epithelial Tumor / Malignant Ovarian Serous Tumor / Ovarian Seromucinous Carcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
2RecruitingTreatmentLeiomyosarcomas1
2RecruitingTreatmentLocalized Urothelial Carcinoma of the Renal Pelvis and Ureter / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter1
2RecruitingTreatmentLocally Advanced / Transitional Cell Carcinoma / Unresectable1
2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
2RecruitingTreatmentLung Cancers1
2RecruitingTreatmentLung Cancers / Untreated Stage IV or Recurrent Squamous Cell Lung Cancers1
2RecruitingTreatmentLymphoma, Extranodal NK-T-Cell1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
2RecruitingTreatmentMalignant Lymphomas2
2RecruitingTreatmentMalignant Neoplasm of Pancreas7
2RecruitingTreatmentMalignant Pleural Mesothelioma (MPM) / Mesothelioma1
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentMetastatic Colorectal Adenocarcinoma1
2RecruitingTreatmentMetastatic Urothelial Carcinoma of the Renal Pelvis and Ureter / Stage IV Bladder Urothelial Carcinoma1
2RecruitingTreatmentMultiple Myeloma (MM)1
2RecruitingTreatmentMuscle-invasive Urothelial Cancer of the Bladder1
2RecruitingTreatmentNasopharyngeal Carcinoma2
2RecruitingTreatmentNeoplasms, Breast1
2RecruitingTreatmentNeoplasms, Pancreatic1
2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2RecruitingTreatmentOvarian Serous Tumor / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2RecruitingTreatmentPancreatic Adenocarcinoma Non-resectable1
2RecruitingTreatmentPancreatic Cancer Metastatic1
2RecruitingTreatmentPancreatic Cancer Stage II1
2RecruitingTreatmentPancreatic Ductal Adenocarcinoma2
2RecruitingTreatmentPancreatic Ductal Carcinoma / Resectable Pancreatic Cancers1
2RecruitingTreatmentPatients Diagnosed With Advanced Carcinoma of Uterine Cervix t1
2RecruitingTreatmentPatients With Stage IV or Recurrent Adenocarcinoma of the Lung1
2RecruitingTreatmentRectal Adenocarcinoma1
2RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2RecruitingTreatmentRenal Cancers1
2RecruitingTreatmentSarcoma, Osteogenic1
2RecruitingTreatmentSarcomas1
2RecruitingTreatmentStage IA Pancreatic Adenocarcinoma / Stage IB Pancreatic Adenocarcinoma / Stage IIA Pancreatic Adenocarcinoma / Stage IIB Pancreatic Adenocarcinoma2
2RecruitingTreatmentStage IIIA Vulvar Cancer / Stage IIIB Vulvar Cancer / Stage IIIC Vulvar Cancer / Stage IVA Vulvar Cancer / Vulvar Squamous Cell Carcinoma1
2RecruitingTreatmentTesticular Cancer2
2RecruitingTreatmentTransitional Cell Carcinoma1
2RecruitingTreatmentTreatment Refusal1
2RecruitingTreatmentUnknown Primary Tumors1
2RecruitingTreatmentUnresectable Pancreatic Cancer1
2RecruitingTreatmentUnresectable Pancreatic Carcinoma1
2RecruitingTreatmentUntreated Metastatic Pancreatic Ductal Adenocarcinoma1
2RecruitingTreatmentUrinary Bladder Neoplasms1
2SuspendedTreatmentBladder Cancers1
2SuspendedTreatmentCancer of the Pancreas / Malignant Neoplasm of Pancreas / Neoplasms Pancreatic / Neoplasms, Pancreatic1
2SuspendedTreatmentMalignant Neoplasm of Pancreas1
2SuspendedTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Carcinosarcoma / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Serous Surface Papillary Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma1
2SuspendedTreatmentTesticular Cancer1
2TerminatedNot AvailableCarcinoma of Unknown Primary1
2TerminatedHealth Services ResearchMalignant Neoplasm of Pancreas1
2TerminatedTreatmentAdenocarcinoma of the Pancreas1
2TerminatedTreatmentAdenocarcinoma of the Pancreas / Locally Advanced / Unresectable1
2TerminatedTreatmentAdenocarcinoma of the Pancreas / Stage III Pancreatic Cancer1
2TerminatedTreatmentAdenocarcinomas / Malignant Neoplasm of Pancreas / Neoplasms Metastasis1
2TerminatedTreatmentBile Duct Carcinoma / Cancer of Gallbladder / Cholangiocarcinomas / Hepatobiliary Neoplasms / Liver Cancer1
2TerminatedTreatmentBile Duct Carcinoma / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocellular Carcinoma / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Hepatocellular,Carcinoma / Periampullary Adenocarcinoma1
2TerminatedTreatmentBiliary Cancer1
2TerminatedTreatmentBiliary Tract Cancer1
2TerminatedTreatmentBladder Cancers3
2TerminatedTreatmentBladder Cancers / Invasive Bladder Cancer1
2TerminatedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2TerminatedTreatmentBladder Cancers / Urinary Bladder1
2TerminatedTreatmentBladder Cancers / Urothelial Cancer1
2TerminatedTreatmentCancer of Pancreas / Cancer of the Pancreas / Malignant Neoplasm of Pancreas1
2TerminatedTreatmentCancer, Breast5
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer2
2TerminatedTreatmentCancer, Ovarian / Peritoneal Cancer1
2TerminatedTreatmentCancers1
2TerminatedTreatmentCancers of the Head and Neck1
2TerminatedTreatmentCarcinoma, Small Cell1
2TerminatedTreatmentCervical Cancers2
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentHead and Neck Carcinoma1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentIntrahepatic Cholangiocarcinoma1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLocally Advanced Biliary Tract Cancer / Metastatic Biliary Tract Cancer1
2TerminatedTreatmentLung Cancers4
2TerminatedTreatmentLymphoma, B-Cell1
2TerminatedTreatmentLymphoma, Extranodal NK-T-Cell1
2TerminatedTreatmentLymphoma, Hodgkins1
2TerminatedTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2TerminatedTreatmentMalignant Neoplasm of Pancreas10
2TerminatedTreatmentMalignant Neoplasm of Pancreas / Neoplasms, Pancreatic2
2TerminatedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Carcinoma Non-resectable1
2TerminatedTreatmentMarginal Zone Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentMetastastic Breast Cancer / Recurrent Breast Cancer1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
2TerminatedTreatmentMetastatic Cancer Pancreas1
2TerminatedTreatmentMetastatic Colorectal Cancers1
2TerminatedTreatmentNeoplasms, Lung1
2TerminatedTreatmentNeoplasms, Ovarian1
2TerminatedTreatmentNeoplasms, Pancreatic1
2TerminatedTreatmentNon-Small-Cell Lung Cancer (NSCLC)2
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)8
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Stage IIIA (N2)1
2TerminatedTreatmentNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer / Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer1
2TerminatedTreatmentOvarian Carcinoma1
2TerminatedTreatmentPancreatic Cancer Metastatic3
2TerminatedTreatmentPancreatic Carcinoma Non-resectable / Stage IV Pancreatic Cancer1
2TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentRenal Cancers1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2TerminatedTreatmentSarcomas1
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2TerminatedTreatmentTransitional Cell Carcinoma1
2TerminatedTreatmentTransitional Cell Carcinoma of the Bladder1
2TerminatedTreatmentUterine Cervical Cancer1
2Unknown StatusSupportive CareSarcomas1
2Unknown StatusTreatmentAdenocarcinoma of the Pancreas1
2Unknown StatusTreatmentAdvanced Pancreatic Cancer1
2Unknown StatusTreatmentBladder Cancers2
2Unknown StatusTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
2Unknown StatusTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Ureteral Cancer / Urethral Cancer1
2Unknown StatusTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2Unknown StatusTreatmentBreast Cancer Stage II / Breast Cancer Stage III1
2Unknown StatusTreatmentCancer, Breast3
2Unknown StatusTreatmentCancer, Ovarian1
2Unknown StatusTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2Unknown StatusTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer2
2Unknown StatusTreatmentCholangiocarcinomas2
2Unknown StatusTreatmentERCC1 / Pancreatic Cancer Metastatic1
2Unknown StatusTreatmentExtrahepatic Bile Duct Cancer / Malignant Neoplasm of Pancreas1
2Unknown StatusTreatmentFallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Cancer1
2Unknown StatusTreatmentGerm Cell Tumors1
2Unknown StatusTreatmentHER2-Negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Unknown StatusTreatmentHead and Neck Carcinoma1
2Unknown StatusTreatmentHepatocellular,Carcinoma1
2Unknown StatusTreatmentLiver Cancer1
2Unknown StatusTreatmentLiver Metastasis1
2Unknown StatusTreatmentLocally Advanced Pancreatic Cancer2
2Unknown StatusTreatmentLung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Stomach / Neuroendocrine Cancer / Non-Small-Cell Lung Carcinoma (NSCLC)1
2Unknown StatusTreatmentLung Cancers8
2Unknown StatusTreatmentLymphoma, Hodgkins1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Unknown StatusTreatmentMalignant Lymphomas1
2Unknown StatusTreatmentMalignant Neoplasm of Pancreas8
2Unknown StatusTreatmentMesothelioma1
2Unknown StatusTreatmentMesothelioma, Malignant1
2Unknown StatusTreatmentNasopharyngeal Carcinoma1
2Unknown StatusTreatmentNeoplasms, Lung1
2Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)7
2Unknown StatusTreatmentOcular Melanoma1
2Unknown StatusTreatmentPancreatic Ductal Carcinoma1
2Unknown StatusTreatmentRelapsed or Metastatic Uterine Leiomyosarcomas or Carcinosarcomas1
2Unknown StatusTreatmentRenal Cancers1
2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)1
2Unknown StatusTreatmentStage IV Nasopharyngeal Carcinoma1
2Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
2WithdrawnTreatmentAdenocarcinoma of the Pancreas1
2WithdrawnTreatmentAdenocarcinoma of the Pancreas / Neoplasms, Pancreatic1
2WithdrawnTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage I Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
2WithdrawnTreatmentAnterior Urethral Cancer / Localized Transitional Cell Cancer of the Renal Pelvis and Ureter / Posterior Urethral Cancer / Recurrent Bladder Cancer / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer / Urethral Cancer Associated With Invasive Bladder Cancer1
2WithdrawnTreatmentCancer, Breast1
2WithdrawnTreatmentCancer, Breast / Non-Small-Cell Lung Carcinoma (NSCLC) / Prostate Cancer1
2WithdrawnTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2WithdrawnTreatmentCancer, Ovarian / Fallopian Tube Neoplasms / Primary Peritoneal1
2WithdrawnTreatmentCarcinoma of Unknown Primary1
2WithdrawnTreatmentCholangiocarcinomas1
2WithdrawnTreatmentHepatocellular,Carcinoma1
2WithdrawnTreatmentLiver Cancer1
2WithdrawnTreatmentLocally Advanced Squamous Non-Small Cell Lung Cancer / Metastatic Squamous Non-small Cell Lung Cancer1
2WithdrawnTreatmentLung Cancers2
2WithdrawnTreatmentMalignant Lymphomas2
2WithdrawnTreatmentMalignant Neoplasm of Pancreas1
2WithdrawnTreatmentNeoplasms, Pancreatic1
2WithdrawnTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2WithdrawnTreatmentPancreatic Adenocarcinoma Metastatic1
2WithdrawnTreatmentPlasma Cell Myeloma1
2WithdrawnTreatmentRenal Cell Adenocarcinoma1
2WithdrawnTreatmentStage III Non-Small Cell Lung Cancer1
2WithdrawnTreatmentTransitional Cell Carcinoma1
2WithdrawnTreatmentUnknown Primary Tumors1
2, 3Active Not RecruitingTreatmentHead and Neck Carcinoma1
2, 3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2, 3Active Not RecruitingTreatmentNon-Small Cell Lung Cancer Recurrent / Non-Small-Cell Lung Carcinoma (NSCLC) / Progression of Non-small Cell Lung Cancer1
2, 3Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
2, 3CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
2, 3CompletedTreatmentBiliary Tract Neoplasms1
2, 3CompletedTreatmentBladder Cancers / Metastasis / Transitional Cell Carcinoma1
2, 3CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2, 3CompletedTreatmentCancer of the Breast / Cancer, Breast / Estrogen Receptor- Negative Breast Cancer / HER2- Negative Breast Cancer / Metastatic Breast Cancer (MBC) / Progesterone Receptor- Negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Cancer (TNBC) / Triple-negative Metastatic Breast Cancer / Tumors, Breast1
2, 3CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
2, 3CompletedTreatmentMalignant Neoplasm of Pancreas4
2, 3Not Yet RecruitingTreatmentBile Duct Carcinoma / Intrahepatic Cholangiocarcinoma1
2, 3Not Yet RecruitingTreatmentGall Bladder Cancers1
2, 3Not Yet RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2, 3Not Yet RecruitingTreatmentPrecancerous Type Pancreatic Cyst1
2, 3RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2, 3RecruitingTreatmentEpstein-Barr Virus Infections / Stage II Nasopharyngeal Carcinoma / Stage III Nasopharyngeal Carcinoma / Stage IVA Nasopharyngeal Carcinoma / Stage IVB Nasopharyngeal Carcinoma1
2, 3RecruitingTreatmentMalignant Neoplasm of Pancreas1
2, 3RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2, 3RecruitingTreatmentResectable Prancreas Carcinoma1
2, 3RecruitingTreatmentUrothelial Advanced or Metastatic Cancer1
2, 3TerminatedTreatmentCancer, Breast / HER2 Positive Breast Cancers1
2, 3TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2, 3Unknown StatusTreatmentLobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma1
2, 3Unknown StatusTreatmentLung Cancers1
2, 3Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
2, 3Unknown StatusTreatmentNasopharyngeal Carcinoma1
2, 3Unknown StatusTreatmentPancreatic Cancer Stage II / Pancreatic Cancer Stage III1
2, 3WithdrawnSupportive CareMalignant Neoplasm of Pancreas1
3Active Not RecruitingTreatmentAdenocarcinoma, Mucinous / Carcinoma, Undifferentiated / Clear Cell Adenocarcinoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinofibroma / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3Active Not RecruitingTreatmentAdenocarcinomas / Non-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentAdvanced Non Small Cell Lung Cancer1
3Active Not RecruitingTreatmentAntimetabolites, Antineoplastic / Digestive System Diseases / Digestive System Neoplasms / Endocrine Gland Neoplasms / Endocrine System Diseases / Gemcitabine / Neoplasms / Neoplasms by Site / Neoplasms, Pancreatic / Pancreatic Diseases1
3Active Not RecruitingTreatmentBiliary Tract Cancer1
3Active Not RecruitingTreatmentBladder Urothelial Carcinoma / Distal Urethral Carcinoma / Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma / Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter / Proximal Urethral Carcinoma / Recurrent Bladder Carcinoma / Recurrent Prostate Carcinoma / Recurrent Urethra Carcinoma / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter / Stage IV Bladder Cancer / Stage IV Prostate Cancer / Stage IV Urethral Cancer / Ureter Carcinoma1
3Active Not RecruitingTreatmentCancer, Breast1
3Active Not RecruitingTreatmentCancer, Ovarian1
3Active Not RecruitingTreatmentDe Novo DLBCL / DLBCL Transformed From Indolent Lymphoma / Follicular Grade 3 Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentLocally Advanced Malignant Neoplasm / Malignant Neoplasm of Pancreas / Pancreatic Carcinoma Non-resectable1
3Active Not RecruitingTreatmentMalignant Lymphomas1
3Active Not RecruitingTreatmentMalignant Neoplasm of Nasopharynx1
3Active Not RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB2
3Active Not RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
3Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
3Active Not RecruitingTreatmentNasopharyngeal Neoplasms1
3Active Not RecruitingTreatmentNon - Small Cell Lung Cancer NSCLC / Non-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentNon Small Cell Lung Cancer (Squamous or Non Squamous)1
3Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma NSCLC1
3Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer / Squamous Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentPeripheral T-cell lymphoma unspecified refractory / Relapsed Peripheral T-Cell Lymphoma1
3Active Not RecruitingTreatmentRecurrent Ovarian Cancer1
3Active Not RecruitingTreatmentStage I Uterine Sarcoma / Stage I Uterine Sarcoma AJCC v7 / Uterine Corpus Leiomyosarcoma1
3Active Not RecruitingTreatmentStage IB Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v71
3Active Not RecruitingTreatmentStage IV or Recurrent Non-Small Cell Lung Cancer1
3CompletedTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Genital Neoplasms, Female / Neoplasms, Ovarian / Pelvic Neoplasms2
3CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IVB Cervical Cancer1
3CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
3CompletedTreatmentAdvanced Non-Small Cell Lung Cancer2
3CompletedTreatmentBladder Cancers2
3CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
3CompletedTreatmentCancer of Cervix1
3CompletedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
3CompletedTreatmentCancer, Breast6
3CompletedTreatmentCancer, Breast / Neoplasms Metastasis1
3CompletedTreatmentCancer, Ovarian5
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer1
3CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Malignant Neoplasm of Pancreas1
3CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer1
3CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
3CompletedTreatmentLocally Advanced Bladder Cancer1
3CompletedTreatmentLocally Advanced Pancreatic Cancer1
3CompletedTreatmentLung Cancers8
3CompletedTreatmentMalignant Neoplasm of Pancreas17
3CompletedTreatmentMetastatic Breast Cancer (MBC)1
3CompletedTreatmentMetastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma1
3CompletedTreatmentMetastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma1
3CompletedTreatmentNeoplasm Metastases / Neoplasms, Pancreatic1
3CompletedTreatmentNeoplasms, Breast1
3CompletedTreatmentNeoplasms, Lung1
3CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
3CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
3CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)11
3CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer2
3CompletedTreatmentNon-small Cell Lung Cancer Stage I and II / Peri-operative Chemotherapy1
3CompletedTreatmentPancreatic Adenocarcinoma Metastatic1
3CompletedTreatmentPancreatic Cancer Metastatic1
3CompletedTreatmentPancreatic Ductal Carcinoma1
3CompletedTreatmentPrimary Peritoneal Carcinoma / Primary Peritoneal Cavity Cancer / Stage III Ovarian Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Cancer / Stage IV Ovarian Epithelial Cancer1
3CompletedTreatmentSoft Tissue Sarcoma (STS)1
3CompletedTreatmentSquamous Cell Carcinoma of Lung1
3CompletedTreatmentStage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
3CompletedTreatmentStage IV Non-Small Cell Lung Cancer1
3CompletedTreatmentTumors, Solid1
3CompletedTreatmentUnknown Primary Neoplasms1
3CompletedTreatmentUnresectable, Metastatic Biliary Tract Carcinoma1
3CompletedTreatmentUrinary Bladder Neoplasms1
3Enrolling by InvitationTreatmentBladder Cancers1
3Enrolling by InvitationTreatmentCancers1
3Not Yet RecruitingTreatmentCancer, Breast1
3Not Yet RecruitingTreatmentCarcinoma,Non-Small-Cell Lung / Lung Carcinomas, Non-Small-Cell / Non-Small-Cell Lung Carcinoma (NSCLC) / Nonsmall Cell Lung Cancer1
3Not Yet RecruitingTreatmentHepatoblastomas / Hepatocellular,Carcinoma1
3Not Yet RecruitingTreatmentIntrahepatic Cholangiocarcinoma1
3Not Yet RecruitingTreatmentLung Cancers1
3Not Yet RecruitingTreatmentMalignant Hydrothorax / Non-Small-Cell Lung Carcinoma (NSCLC)1
3Not Yet RecruitingTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
3Not Yet RecruitingTreatmentPleural Mesothelioma Malignant Advanced1
3RecruitingBasic ScienceUrinary Bladder Neoplasms1
3RecruitingPreventionCholangiocarcinomas1
3RecruitingTreatmentBRCA Rearrangement / Deleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Endometrial Undifferentiated Carcinoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Tumor / Ovarian Seromucinous Carcinoma / Ovarian Serous Tumor / Ovarian Transitional Cell Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3RecruitingTreatmentBladder Cancers / Urothelial Cancer1
3RecruitingTreatmentBreast Cancer Model / Cancer, Breast / Effects of Chemotherapy1
3RecruitingTreatmentCancer, Breast2
3RecruitingTreatmentCancer, Breast / Metastasis1
3RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Ovarian Epithelial Cancer / Peritoneal Cancer1
3RecruitingTreatmentCarcinoma NOS / Malignant Neoplasm of Pancreas1
3RecruitingTreatmentCervical Cancers1
3RecruitingTreatmentCholangiocarcinomas1
3RecruitingTreatmentCholangiocarcinomas / Gall Bladder Carcinoma1
3RecruitingTreatmentExtranodal NK-T-Cell Lymphoma, Nasal Type1
3RecruitingTreatmentExtranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type1
3RecruitingTreatmentFirst Line Non-Small Cell Lung Cancer1
3RecruitingTreatmentHER-2 Positive Breast Cancer / Neoplasms, Metastatic1
3RecruitingTreatmentHER2-positive Locally Advanced or Metastatic Breast Cancer1
3RecruitingTreatmentLocally Advanced Pancreatic Cancer / Neoplasms, Pancreatic / Pancreatic Cancer Metastatic1
3RecruitingTreatmentLymphoma, Extranodal NK-T-Cell1
3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
3RecruitingTreatmentMalignant Lymphomas1
3RecruitingTreatmentMalignant Neoplasm Other Gallbladder/Extrahepatic Bile Duct1
3RecruitingTreatmentMalignant Neoplasm of Pancreas5
3RecruitingTreatmentNasopharyngeal Neoplasms1
3RecruitingTreatmentNeoplasms, Ovarian1
3RecruitingTreatmentNon Small Cell Lung Cancer NSCLC / Non-Small-Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC) / Non Small Cell Lung Carcinoma NSCLC2
3RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)3
3RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer / Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer1
3RecruitingTreatmentPancreatic Acinar Cell Carcinoma / Pancreatic Ductal Adenocarcinoma / Pancreatic Intraductal Papillary-Mucinous Neoplasm / Stage IA Pancreatic Cancer / Stage IA Pancreatic Cancer AJCC v6 and v7 / Stage IB Pancreatic Cancer / Stage IB Pancreatic Cancer AJCC v6 and v7 / Stage IIA Pancreatic Cancer / Stage IIA Pancreatic Cancer AJCC v6 and v7 / Stage IIB Pancreatic Cancer / Stage IIB Pancreatic Cancer AJCC v6 and v71
3RecruitingTreatmentPancreatic Ductal Adenocarcinoma / Stage IV Pancreatic Ductal Adenocarcinoma1
3RecruitingTreatmentPancreatic Ductal Carcinoma1
3RecruitingTreatmentResected Pancreatic Adenocarcinoma1
3RecruitingTreatmentStage III Intrahepatic Cholangiocarcinoma / Stage IVA Intrahepatic Cholangiocarcinoma1
3RecruitingTreatmentStage ⅡA Pancreatic Cancer / Stage ⅡB Pancreatic Cancer1
3RecruitingTreatmentTransitional Cell Carcinoma1
3RecruitingTreatmentTransitional Cell Carcinoma of Ureter1
3RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
3RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
3RecruitingTreatmentUrothelial Cancer1
3RecruitingTreatmentUrothelial Carcinoma Associated 1 RNA, Human1
3TerminatedPreventionHepatocellular,Carcinoma / Liver Cirrhosis / Neoplasm Recurrence, Local / Neoplasms, Hepatic / Recurrences1
3TerminatedTreatmentAdenocarcinoma of the Pancreas / Advanced Malignancy / Advanced Solid Tumors / Bone Metastases / Cancer of Pancreas / Cancer of the Pancreas / Cancers / Endocrine Cancer / Malignant Neoplasm of Pancreas / Metastases / Metastatic Cancers / Oncology / Oncology Patients / Pancreatic Cancer Metastatic / Tumors, Solid1
3TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer1
3TerminatedTreatmentAdvanced Unresectable Pancreatic Cancer1
3TerminatedTreatmentBladder Cancers1
3TerminatedTreatmentCancer, Breast1
3TerminatedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
3TerminatedTreatmentHilar Cholangiocarcinoma1
3TerminatedTreatmentLung Cancers3
3TerminatedTreatmentMalignant Lymphomas1
3TerminatedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Cancer Metastatic1
3TerminatedTreatmentMalignant Neoplasm of Pancreas / Thromboembolism1
3TerminatedTreatmentMetastatic Pancreatic Ductal Adenocarcinoma1
3TerminatedTreatmentNeoplasm, Bladder1
3TerminatedTreatmentNeoplasms, Pancreatic1
3TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
3TerminatedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
3TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
3TerminatedTreatmentRecurrent Uterine Corpus Sarcoma / Stage IIIA Uterine Sarcoma / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma / Uterine Corpus Leiomyosarcoma1
3Unknown StatusNot AvailableMalignant Neoplasm of Pancreas1
3Unknown StatusTreatmentAdvanced Breast Cancer1
3Unknown StatusTreatmentAggressive B Cell Lymphoma1
3Unknown StatusTreatmentBladder Cancers1
3Unknown StatusTreatmentBladder Cancers / Transitional Cell Carcinoma1
3Unknown StatusTreatmentCancer, Breast2
3Unknown StatusTreatmentCarcinoma NOS1
3Unknown StatusTreatmentCervical Cancers1
3Unknown StatusTreatmentEffects of Chemotherapy / Stage IVC Nasopharyngeal Carcinoma1
3Unknown StatusTreatmentLung Cancers6
3Unknown StatusTreatmentMalignant Neoplasm of Pancreas8
3Unknown StatusTreatmentMetastatic Breast Cancer (MBC)1
3Unknown StatusTreatmentMetastatic Pancreas Cancer1
3Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3WithdrawnTreatmentCervical Cancers1
3WithdrawnTreatmentHepatocellular,Carcinoma1
3WithdrawnTreatmentLung Cancers2
3WithdrawnTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
4Active Not RecruitingNot AvailableMalignant Neoplasm of Pancreas1
4Active Not RecruitingTreatmentAdenocarcinomas / EGFR Positive Non-small Cell Lung Cancer1
4CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
4Not Yet RecruitingTreatmentLung Squamous Cell Carcinoma1
4RecruitingTreatmentAdenocarcinoma of the Pancreas1
4RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)1
4TerminatedTreatmentMalignant Neoplasm of Pancreas1
4Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
Not AvailableActive Not RecruitingBasic ScienceMalignant Neoplasm of Pancreas1
Not AvailableActive Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
Not AvailableActive Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
Not AvailableActive Not RecruitingTreatmentOf the Pancreas / Previously Untreated Resectable Adenocarcinoma of the Pancreas / Subjects Must Have Previously Untreated Apparently Resectable Adenocarcinoma1
Not AvailableCompletedNot AvailableCancer, Breast / Metastatic Cancers1
Not AvailableCompletedNot AvailableNeoplasms1
Not AvailableCompletedNot AvailableNon-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedSupportive CareExtrahepatic Bile Duct Cancer / Nausea / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Vomiting1
Not AvailableCompletedTreatmentMalignant Neoplasm of Pancreas2
Not AvailableCompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
Not AvailableNot Yet RecruitingTreatmentAdenocarcinoma of the Pancreas1
Not AvailableNot Yet RecruitingTreatmentInfiltrating Bladder Urothelial Carcinoma / Stage II Bladder Urothelial Carcinoma / Stage III Bladder Urothelial Carcinoma / Stage IV Bladder Urothelial Carcinoma1
Not AvailableNot Yet RecruitingTreatmentMalignant Neoplasm of Pancreas1
Not AvailableRecruitingNot AvailablePancreatic Cancer Metastatic1
Not AvailableRecruitingDiagnosticMalignant Neoplasm of Pancreas1
Not AvailableRecruitingTreatmentAdvanced Pancreatic Ductal Adenocarcinoma / Malignant Neoplasm of Pancreas1
Not AvailableRecruitingTreatmentBladder Cancers / Epirubicin Instillation / Gemcitabine and Cisplatin Chemotherapy / Prognosis / Recurrences1
Not AvailableRecruitingTreatmentGallbladder Cancer1
Not AvailableRecruitingTreatmentIntrahepatic Cholangiocarcinoma1
Not AvailableRecruitingTreatmentMalignant Neoplasm of Pancreas1
Not AvailableRecruitingTreatmentNasopharyngeal Neoplasms1
Not AvailableRecruitingTreatmentRecurrent Fallopian Tube Cancer / Recurrent Ovarian Cancer / Recurrent Primary Peritoneal Cancer / Recurrent Uterine Corpus Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IIIC Uterine Corpus Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cavity Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
Not AvailableRecruitingTreatmentResectable Pancreatic Cancers1
Not AvailableTerminatedNot AvailableCancer, Breast1
Not AvailableTerminatedTreatmentMalignant Neoplasm of Pancreas1
Not AvailableTerminatedTreatmentMalignant Neoplasm of Pancreas / Malnutrition1
Not AvailableTerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
Not AvailableTerminatedTreatmentResectable Intrahepatic Cholangiocarcinoma / Unresectable Intrahepatic Cholangiocarcinoma1
Not AvailableTerminatedTreatmentSarcoma, Osteogenic1
Not AvailableUnknown StatusTreatmentChemotherapy, Adjuvant / Hepatocellular,Carcinoma / Survival / Transplantation, Liver / Tumor Recurrence and Metastasis1
Not AvailableUnknown StatusTreatmentMalignant Neoplasm of Pancreas2
Not AvailableUnknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
Not AvailableUnknown StatusTreatmentStage IA Uterine Sarcoma / Stage IB Uterine Sarcoma / Stage IC Uterine Sarcoma / Stage IIA Uterine Sarcoma / Stage IIB Uterine Sarcoma / Stage IIIA Uterine Sarcoma / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma / Uterine Corpus Leiomyosarcoma1
Not AvailableWithdrawnTreatmentMalignant Neoplasm of Pancreas1
Pharmacoeconomics
Manufacturers
  • Teva parenteral medicines inc
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous38 mg/mL
Injection, powder, lyophilized, for solutionIntravenous1 g/26.3mL
Injection, powder, lyophilized, for solutionIntravenous200 mg/5.26mL
Injection, powder, lyophilized, for solutionIntravenous38 mg/mL
Injection, powder, lyophilized, for solutionIntravenous40 mg/mL
Injection, solutionIntravenous38 mg/mL
SolutionIntravenous100 mg
PowderIntravenous1 g
PowderIntravenous2 g
PowderIntravenous200 mg
Powder, for solutionIntravenous2 g
Powder, for solutionIntravenous200 mg
Injection, powder, lyophilized, for solutionIntravenous1 g/25mL
Injection, powder, lyophilized, for solutionIntravenous2 g/50mL
Injection, powder, lyophilized, for solutionIntravenous200 mg/5mL
Powder, for solutionIntravenous1 g
SolutionIntravenous38 mg
SolutionIntravenous40 mg
Prices
Unit descriptionCostUnit
Gemzar 1 gm Solution Vial903.93USD vial
Gemzar 1 gram vial869.16USD vial
Gemzar 200 mg Solution Vial180.78USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5464826 No1993-05-072013-05-07Us
US4808614 No1993-05-152010-05-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)168.64 °CNot Available
water solubilitySolubleNot Available
logP-1.4Not Available
pKa3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility22.3 mg/mLALOGPS
logP0.14ALOGPS
logP-1.5ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)11.52ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area108.38 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity53.25 m3·mol-1ChemAxon
Polarizability21.45 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9814
Blood Brain Barrier+0.9693
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.8317
P-glycoprotein inhibitor INon-inhibitor0.9557
P-glycoprotein inhibitor IINon-inhibitor0.9106
Renal organic cation transporterNon-inhibitor0.939
CYP450 2C9 substrateNon-substrate0.8634
CYP450 2D6 substrateNon-substrate0.8484
CYP450 3A4 substrateNon-substrate0.6016
CYP450 1A2 substrateNon-inhibitor0.8958
CYP450 2C9 inhibitorNon-inhibitor0.8633
CYP450 2D6 inhibitorNon-inhibitor0.8787
CYP450 2C19 inhibitorNon-inhibitor0.8478
CYP450 3A4 inhibitorNon-inhibitor0.9032
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8862
Ames testNon AMES toxic0.6793
CarcinogenicityNon-carcinogens0.8286
BiodegradationNot ready biodegradable0.9948
Rat acute toxicity2.1220 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9948
hERG inhibition (predictor II)Non-inhibitor0.8314
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-03di-0930000000-e2122f1423d3060097b9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-03di-0790000000-e66897c78fa010a45ab8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0cfs-0910000000-e4e73c07b687772a1108View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0a4i-0900000000-99f619802e3ba7bd8b2eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0a4i-0900000000-18dd55d7372a11b9dfb7View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0a4i-1900000000-fdc016f6d17808e4cf1bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0a4i-5900000000-ec478d4dfe03f80b91adView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-03di-0790000000-0d953fc9632751f00f72View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-07xs-0920000000-0e8154089a57b6bef7c4View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0a4i-0900000000-c54a530153a028d6ffccView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0a4i-0900000000-1f4cd6bc7d377fe7731eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0a4i-0900000000-c3cdcfa5d386ac7222faView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0aor-4900000000-337f45a27b7b12b1b2f0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-03di-0920000000-52d24e07b71b7d08dcdbView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-03di-0190000000-6d052797bc5b8b31bf7bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-03dl-0900000000-01d92fca070f980c2668View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-0900000000-95712722811cd50ab160View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-0190000000-b97d64dba479bbac0253View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-0930000000-fce77aa139fbedd4910bView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.
KingdomOrganic compounds
Super ClassNucleosides, nucleotides, and analogues
ClassPyrimidine nucleosides
Sub ClassPyrimidine 2'-deoxyribonucleosides
Direct ParentPyrimidine 2'-deoxyribonucleosides
Alternative ParentsPyrimidones / Aminopyrimidines and derivatives / Hydropyrimidines / Imidolactams / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Fluorohydrins / Azacyclic compounds / Oxacyclic compounds
SubstituentsPyrimidine 2'-deoxyribonucleoside / Aminopyrimidine / Pyrimidone / Hydropyrimidine / Pyrimidine / Imidolactam / Heteroaromatic compound / Tetrahydrofuran / Fluorohydrin / Halohydrin
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorsorganofluorine compound, pyrimidine 2'-deoxyribonucleoside (CHEBI:175901 )

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Hastak K, Alli E, Ford JM: Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010 Oct 15;70(20):7970-80. doi: 10.1158/0008-5472.CAN-09-4521. Epub 2010 Aug 26. [PubMed:20798217 ]
  2. Ledermann JA, Gabra H, Jayson GC, Spanswick VJ, Rustin GJ, Jitlal M, James LE, Hartley JA: Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin Cancer Res. 2010 Oct 1;16(19):4899-905. doi: 10.1158/1078-0432.CCR-10-0832. Epub 2010 Aug 18. [PubMed:20719935 ]
  3. Garcia-Diaz M, Murray MS, Kunkel TA, Chou KM: Interaction between DNA Polymerase lambda and anticancer nucleoside analogs. J Biol Chem. 2010 May 28;285(22):16874-9. doi: 10.1074/jbc.M109.094391. Epub 2010 Mar 26. [PubMed:20348107 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor
Specific Function:
Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides.
Gene Name:
RRM1
Uniprot ID:
P23921
Uniprot Name:
Ribonucleoside-diphosphate reductase large subunit
Molecular Weight:
90069.375 Da
References
  1. Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC: Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics. 2006 Jun;16(6):429-38. [PubMed:16708051 ]
  2. Rosell R, Cobo M, Isla D, Camps C, Massuti B: Pharmacogenomics and gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v13-16. [PubMed:16807441 ]
  3. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006 Oct 10;24(29):4731-7. Epub 2006 Sep 11. [PubMed:16966686 ]
  4. Smid K, Bergman AM, Eijk PP, Veerman G, van Haperen VW, van den Ijssel P, Ylstra B, Peters GJ: Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1001-7. [PubMed:17065054 ]
  5. Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer. 2007 Mar 15;120(6):1355-63. [PubMed:17131328 ]
  6. Cerqueira NM, Fernandes PA, Ramos MJ: Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry. 2007;13(30):8507-15. [PubMed:17636467 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Thymidylate synthase activity
Specific Function:
Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name:
TYMS
Uniprot ID:
P04818
Uniprot Name:
Thymidylate synthase
Molecular Weight:
35715.65 Da
References
  1. Rosell R, Taron M, Sanchez JM, Moran T, Reguart N, Besse B, Isla D, Massuti B, Alberola V, Sanchez JJ: The promise of pharmacogenomics: gemcitabine and pemetrexed. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):70-6. [PubMed:15655942 ]
  2. Huang CL, Yokomise H, Fukushima M, Kinoshita M: Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol. 2006 Apr;2(2):289-99. [PubMed:16563096 ]
  3. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28. [PubMed:15795320 ]
  4. Zhao XD, Zhang Y: [Routine chemotherapeutic drug treatment effectiveness predictive molecules and chemotherapeutic drug selection]. Ai Zheng. 2006 Dec;25(12):1577-80. [PubMed:17166391 ]
  5. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R: Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther. 2006 Jun;5(6):1387-95. [PubMed:16818496 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Marce S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M, Colomer D: Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica. 2006 Jul;91(7):895-902. [PubMed:16818276 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Uridylate kinase activity
Specific Function:
Catalyzes the phosphorylation of pyrimidine nucleoside monophosphates at the expense of ATP. Plays an important role in de novo pyrimidine nucleotide biosynthesis. Has preference for UMP and CMP as phosphate acceptors. Also displays broad nucleoside diphosphate kinase activity.
Gene Name:
CMPK1
Uniprot ID:
P30085
Uniprot Name:
UMP-CMP kinase
Molecular Weight:
22222.175 Da
References
  1. Vernejoul F, Ghenassia L, Souque A, Lulka H, Drocourt D, Cordelier P, Pradayrol L, Pyronnet S, Buscail L, Tiraby G: Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther. 2006 Dec;14(6):758-67. Epub 2006 Sep 25. [PubMed:17000136 ]
  2. Hsu CH, Liou JY, Dutschman GE, Cheng YC: Phosphorylation of Cytidine, Deoxycytidine, and Their Analog Monophosphates by Human UMP/CMP Kinase Is Differentially Regulated by ATP and Magnesium. Mol Pharmacol. 2005 Mar;67(3):806-14. Epub 2004 Nov 18. [PubMed:15550676 ]
  3. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG: Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 2005;5(4):226-43. [PubMed:16041392 ]
  4. Lam W, Leung CH, Bussom S, Cheng YC: The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine. Mol Pharmacol. 2007 Sep;72(3):536-44. Epub 2007 Jun 12. [PubMed:17565005 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.
Gene Name:
CDA
Uniprot ID:
P32320
Uniprot Name:
Cytidine deaminase
Molecular Weight:
16184.545 Da
References
  1. Giovannetti E, Laan AC, Vasile E, Tibaldi C, Nannizzi S, Ricciardi S, Falcone A, Danesi R, Peters GJ: Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):720-5. doi: 10.1080/15257770802145447. [PubMed:18600531 ]
  2. Gusella M, Pasini F, Bolzonella C, Meneghetti S, Barile C, Bononi A, Toso S, Menon D, Crepaldi G, Modena Y, Stievano L, Padrini R: Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44. doi: 10.1111/j.1365-2125.2010.03838.x. [PubMed:21284703 ]
  3. Wong A, Soo RA, Yong WP, Innocenti F: Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev. 2009;41(2):77-88. doi: 10.1080/03602530902741828. [PubMed:19514966 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents.
Gene Name:
DCK
Uniprot ID:
P27707
Uniprot Name:
Deoxycytidine kinase
Molecular Weight:
30518.315 Da
References
  1. Wong A, Soo RA, Yong WP, Innocenti F: Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev. 2009;41(2):77-88. doi: 10.1080/03602530902741828. [PubMed:19514966 ]
  2. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Deviere J, Van Laethem JL: Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer. 2010 Nov 15;116(22):5200-6. doi: 10.1002/cncr.25303. [PubMed:20669326 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
References
  1. Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL, Peters GJ: Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003 Jun 16;88(12):1963-70. [PubMed:12799644 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Uniprot Name:
Multidrug resistance-associated protein 7
Molecular Weight:
161627.375 Da
References
  1. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Nucleoside transmembrane transporter activity
Specific Function:
Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs).
Gene Name:
SLC29A1
Uniprot ID:
Q99808
Uniprot Name:
Equilibrative nucleoside transporter 1
Molecular Weight:
50218.805 Da
References
  1. Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, Cass C, Ruffini PA, Spoto C, Muretto P, Rizzo S, Muda AO, Mackey JR, Russo A, Tonini G, Graziano F: Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol. 2010 May;223(2):384-8. doi: 10.1002/jcp.22045. [PubMed:20082300 ]
  2. Marce S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M, Colomer D: Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica. 2006 Jul;91(7):895-902. [PubMed:16818276 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Pyrimidine- and adenine-specific:sodium symporter activity
Specific Function:
Sodium-dependent and pyrimidine-selective. Exhibits the transport characteristics of the nucleoside transport system cit or N2 subtype (N2/cit) (selective for pyrimidine nucleosides and adenosine). It also transports the antiviral pyrimidine nucleoside analogs 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC). It may be involved in the intestinal absorption and renal handling of ...
Gene Name:
SLC28A1
Uniprot ID:
O00337
Uniprot Name:
Sodium/nucleoside cotransporter 1
Molecular Weight:
71583.18 Da
References
  1. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young JD: Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst. 1999 Nov 3;91(21):1876-81. [PubMed:10547395 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Nucleoside transmembrane transporter activity
Specific Function:
Mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Very less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, dilazep and draflazine.
Gene Name:
SLC29A2
Uniprot ID:
Q14542
Uniprot Name:
Equilibrative nucleoside transporter 2
Molecular Weight:
50112.335 Da
References
  1. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young JD: Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst. 1999 Nov 3;91(21):1876-81. [PubMed:10547395 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Pyrimidine- and adenine-specific:sodium symporter activity
Specific Function:
Sodium-dependent, pyrimidine- and purine-selective. Involved in the homeostasis of endogenous nucleosides. Exhibits the transport characteristics of the nucleoside transport system cib or N3 subtype (N3/cib) (with marked transport of both thymidine and inosine). Employs a 2:1 sodium/nucleoside ratio. Also able to transport gemcitabine, 3'-azido-3'-deoxythymidine (AZT), ribavirin and 3-deazaurid...
Gene Name:
SLC28A3
Uniprot ID:
Q9HAS3
Uniprot Name:
Solute carrier family 28 member 3
Molecular Weight:
76929.61 Da
References
  1. Govindarajan R, Leung GP, Zhou M, Tse CM, Wang J, Unadkat JD: Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G910-22. doi: 10.1152/ajpgi.90672.2008. Epub 2009 Jan 22. [PubMed:19164483 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 15:53